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SUMMARY 
Breast cancer is the most common cancer among women in many parts of the world 
and early detection is the key to the survival of the patients. There is evidence that changes in 
HER2 and p53 protein expression might be relevant to breast cancer progression. 
Furthermore, we have recently reported that malignant breast tumors show an altered 
expression of Fas and Fas ligand (FasL) compared to normal tissues and these molecular 
changes are significantly related to patient outcome and COX2 is a relevant new prognostic 
marker. In this study we hypothesized that these molecular markers might also be useful to 
evaluate the malignant potential of non-neoplastic breast tissues. 
To this end, we analyzed, by using specific antibodies, HER2, p53, Fas and FasL expression 
in 72 breast carcinomas, the corresponding autologous peritumoral tissues (PTT) sampled at 
1, 2 and 3 cm far from the tumor itself and in 44 benign mammary lesions. Ten breast 
carcinomas and their autologous 1 cm PTT samples were also analyzed by fluorescent in situ 
hybridization (FISH) to determine if HER2 gene amplification can be demonstrated in the 
background of cytoplasmic immunohistochemical HER2 staining. Further 186 stage I-II 
primary BC and 95 autologous metastatic lymphnodes were analyzed immunohistochemically 
for COX2, hormones receptor, p53, HER2, Fas and Fas ligand (FasL) expression to determine 
the effect of COX2 expression on the prognosis of breast cancer patients receiving 
chemotherapy either as a single factor or taken into consideration together with other factors. 
To understand better the probable role of functional COX2 alteration in developing primary 
breast cancer and metastases, we also analyzed the expression of PGE2S in 121 primary breast 
tumors and of epidermal growth factor receptor (EGFR) in 167 of the cases Because of 
insufficient quantity of tissue samples no complete analyses for all the 186 cases and their 95 
metastases were available. 
Results obtained suggest that HER2 gene amplification often underlies even cytoplasmic 
HER2 staining when analyzed immunohistochemically. Furthermore, breast carcinomas and 
the closest adjacent uninvolved parenchyma shared an upregulated FasL phenotype which is 
lost in PTT farther from the tumor. Therefore, among the biological parameters investigated, 
HER2 and FasL expression seems to represent biomarkers of breast tumorigenesis easily 
applicable to fine needle aspirates and potentially useful to detect patients at high risk of 
breast carcinoma. Moreover, in high-risk breast cancer patients the immunohistochemical 
evaluation of COX2, together with PGE2S, p53, Ki67, HER2, Fas and FasL, may be of 
clinical value in distinguishing different responses to adjuvant anthracycline-based 
chemotherapy. 
 4
1. INTRODUCTION 
About 180.000 new cases of breast cancer (BC) are diagnosed yearly and despite 
improvements in screening programs and integrated treatments, mortality from this cancer has 
only moderately decreased, suggesting that this malignancy, at diagnosis, is often a systemic 
disease. Therefore early detection is, at the present, the key strategy to improve the outcome 
of patients bearing this neoplasia. The development and progression of BC, as in other solid 
tumors, result from the accumulation of genetic alterations. Therefore it is likely that some 
types of benign lesions (BL), precursors for invasive BC and the normal appearing 
peritumoral tissue (PTT), according to the field cancerization hypothesis, may harbor 
molecular changes representing signatures of clinical relevance which heralds early stages of 
cancer development. In BC this hypothesis is becoming increasingly supported by 
experimental data. At genetic level, it has been reported that the frequency of chromosomal 
abnormalities found in benign tumors, although lower than in BC, correlates with the 
corresponding risk of developing invasive carcinoma (1). Moreover, the benign parenchyma 
of cancer-containing breast and the contralateral epithelium in patients who experienced 
cancer in one breast, can share with invasive carcinoma the same pattern of chromosomal 
abnormalities (2). 
The analysis of tumor suppressor genes has demonstrated that p53 gene mutation and protein 
nuclear accumulation can be detected in benign breast lesions (3, 4) as well as in normal 
breast epithelium adjacent to excised tumor (5, 6). These findings suggest that perturbations 
in p53 function may occur in breast tissue before morphological changes are apparent. 
Although it is often assumed that somatic p53 mutations not altering coding may be silent, 
such alterations could still serve as an index of accumulating genetic damage and/or defects in 
DNA repair. 
The scrutiny of changes in expression pattern of oncogene products associated with 
unfavorable prognosis has revealed that overexpression of HER2 (7) is an early event in 
breast carcinogenesis since it is detected in a higher percentage of in situ carcinoma than of 
the invasive one (8). Furthermore, HER2 gene amplification and protein overexpression can 
be found in benign proliferative breast lesions such as typical (TDH) and atypical ductal 
hyperplasia (ADH) and in morphologically normal appearing mammary epithelium adjacent 
to invasive cancer (6, 9, 10). Cell cycle control is a highly complex finely tuned process in 
which genes modulating cell proliferation i.e. p53, HER2 are balanced by gene products 
controlling apoptosis such as the Fas-FasL system. In this context we have reported that 
benign and malignant mammary lesions are characterized by differential expression of this 
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complementary receptor/ligand antigen and that a tumor with a Fas-/FasL+ phenotype is 
associated with an unfavorable outcome (11). Because Fas is more homogeneously expressed 
in benign than in malignant tumors (11, 12, 13) and BRCA-1 associated cancers express 
higher level of FasL than the sporadic disease, changes in Fas/FasL phenotype might 
represent an early biomarker of transformation. To address this issue in the present study we 
extended the analysis of Fas/FasL expression to the normal appearing PTT. To this end we 
submitted to a parallel immunohistochemical (IHC) analysis, which included HER2, p53, Fas 
and FasL, 72 BC and multiple samples of the autologous normal appearing peritumoral 
epithelium sampled at 1, 2 and 3 cm from invasive cancer to determine whether a gradient of 
molecular alterations may occur. 
Recent epidemiologic studies have indicated that prolonged use of nonsteroidal anti-
inflammatory drugs (NSAID) is associated with a decreased risk of several malignancies, 
most notably colorectal cancers (14, 15, 16, 17). Similar relationships have been observed in 
lung, breast and other cancers as well (18, 19). Since NSAID, as a principal action, inhibit 
cyclooxygenases, these findings suggest that cyclooxygenase (COX) activity and thus 
prostaglandin (PG) synthesis contributes to the risk of developing primary cancers (20). High 
COX expression is a common feature of human epithelial malignancies (21, 22), however, the 
biological significance of this metabolic activity is not completely clear yet. Two isoforms of 
COX are known: COX1 is expressed ubiquitously, and its role has been connected to 
physiological functions such as maintenance of the gastric mucosa and regulation of the renal 
blood flow, whereas COX2 is induced as an immediate-early gene in most cells and its 
expression is not detectable in most healthy tissues, but can be induced in response to various 
extracellular stimuli, including growth factors, cytokines, tumor promoters, peroxisomal 
proliferators and carcinogens (16). Additionally, COX2 is responsive also to several 
oncogenes (23, 24, 25). Even though cancer cell lines express both COX isoforms, the 
majority of the PG synthesis - which may be inhibited by the NSAID administration - stems 
from the activity of the inducible COX2 isoform (22). COX2 is known to induce 
prostaglandin E2 synthase (PGE2S) activity (26) while synthesized PGE2 is related also to the 
metastatic ability of the primary tumor (27). COX2 also induces epidermal growth factor 
receptor (EGFR) expression and thus mediates trophic actions on gastrointestinal mucosa in 
human colon cancer cell lines (28). 
In contrast to colon cancer, the role of COX2 in breast cancer is less clear. Poorly 
differentiated histological features were found to correlate with low COX2 expression in 
mammary, pulmonary and colonic tumors. In breast carcinomas, in situ malignancies were 
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more likely to express COX2 than invasive carcinomas (29). Furthermore, in a murine model 
system positive correlation of both COX2 expression and metabolic activity to tumorigenic 
and metastatic potential was shown (30). It has also been revealed that high levels of COX2 
are expressed in human mammary tumor tissues compared to the adjacent normal tissue (31), 
which may indicate an induced COX2 function due to the changes the malignant cells have 
undergone. Several studies have revealed an association between NSAID consumption (and 
thus inhibition of COX2 activity) and decreased breast carcinoma incidence (18, 32, 33), 
while others have failed to find a significant relationship between aspirin use and breast 
cancer risk (14, 34). The basis for this lack of consistency among different studies is unclear. 
Conflicting data obtained in separate studies may reflect the usage of different NSAID in the 
populations examined. Another potential explanation is that significant COX2 overexpression 
may be limited to a subset of human breast cancers (20). 
To this end 186 stage I-II primary BC and 95 autologous lymph node metastases were 
analyzed immunohistochemically for COX2, hormones receptor, p53, HER2, Ki67, Fas and 
FasL expression to determine the effect of COX2 expression on the prognosis of breast cancer 
patients receiving chemotherapy. To understand better the probable role of functional COX2 
alteration in developing primary breast cancer and metastases, we also analyzed the 
expression of PGE2S in 121 primary breast tumors and of epidermal growth factor receptor 
(EGFR) in 167 of the cases. Because of insufficient quantity of tissue samples no complete 
analyses for all the 186 cases and their 95 metastases were possible. 
 
1.1 AIMS 
Since the development and progression of breast cancer, as in other solid tumors, 
result from the accumulation of genetic alterations, it is likely that some types of benign 
lesions, precursors for invasive breast cancer and the normal appearing peritumoral tissue, 
according to the field effect hypothesis, may harbor molecular changes representing 
signatures of clinical relevance which heralds early stages of cancer development. 
The aims of our two studies were 
1. to determine immunohistochemically the HER2, p53, Fas, FasL, hormone receptores, 
COX2, PGE2S and EGFR expression in breast cancer tissues and in morphologically 
normal-appearing peritumoral tissue samples taken 1cm, 2 cm and 3 cm far from the 
tumors. 
2. To determine HER2 gene amplification by FISH in HER2 positive 1 cm peritumoral 
tissue samples to support the field-effect hypothesis. 
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3. To determine the influence of the investigated markers on the 5-year disease-free 
survival and overall survival of the breast cancer patients. 
4. To determine the combination of markers most useful to determine accurate prognosis. 
5. To establish a set of markers for diagnosing high risk of recurrence by determining 
field-effect in peritumoral tissue samples. 
 
1.2. HISTORY OF BREAST CANCER  
The oldest record of breast cancer dates back to 1600 BC. This document is the oldest 
known medical record and supposed to be a transcript made in 1600 BC of a papyrus dating 
back to about 3000 BC (35). 
Celsus realized the value of surgery in the early stages of the breast tumor and said that only 
small tumors could be removed, while larger tumors would only be irritated by surgical 
intervention. Hippocrate (460 AD) distinguished between benign and malignant tumors. He 
considered breast cancer incurable (36). According to the doctrines of Galen (130-200 AD), 
melancholia was the main factor in the development of breast cancer. Special diets and 
exorcism were the recommended treatments. 
An English physician, Thomas Willis (1621-1675), used almost the same definition of tumor 
with respect to neoplasia as it is used today. According to him, tumor is the disturbance of 
growing primary characterized cells with uncontrolled, non-purposefully dividing cells  
During the Renaissance, Andreas Vesalius recommended mastectomy as well as ligatures 
(sutures) to control the bleeding, rather than cauterization. The fact that breast cancer could 
spread to the regional axillary nodes was first recognized by the physician LeDran (1685-
1770) who was probably the very first person in history to associate poor prognosis with the 
spread of breast cancer to the lymph nodes (37). 
The first epidemiological data of breast cancer came from Middlesex Hospital in London 
(1791-1805), where the first breast cancer cases were registered. Two hundred-fifty of these 
patients refused treatment (37). Although anatomical knowledge improved in the 18th century, 
the outcome of breast surgery did not, due to infection, lack of good anesthesia, and the use of 
complete radical mastectomy. A new era of surgery and medicine began with the discovery of 
NO as an anesthetic in 1846, antiseptic techniques in 1867, and microscopic histological 
analysis. 
Halstead and Meyer brought light to the ill-fortuned women diagnosed with breast cancer. In 
1894 each of them independently announced his surgical procedures and results for treatment 
of breast cancer. They described, for that period of time, a superior local control of disease by 
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en-bloc radical mastectomy which included total removal of the affected breast, total 
ipsilateral axillary lymph node dissection in levels I-III, resection of pectoral major and minor 
muscles, and routine resection of the thoracodorsal neurovascular network including the long 
thoracic nerve (37, 38). 
During the mid-1900s, X-ray diagnosis of breast improved so dramatically that detection of 
non-palpable tumor in the breast was enabled. This allowed new surgical operations such as 
lumpectomy, quadrantectomy and segmentectomy to be used. 
From 1896, when Beatson published that the surgical castration (bilateral oophorectomy) of 
two patients resulted in tumor regression, hormonal therapy of breast cancer has progressed 
through several stages, but correlation between hormones and tumor growth was not proved 
until hormonal receptors were discovered on breast cancer cells (35). In 1955 Engell 
published evidence of hematogenous dissemination of malignant cells. This research forced 
efforts for systemic chemotherapeutic and immunotherapeutic agents for the treatment of 
metastatic breast cancer. 
 
1.3. EPIDEMIOLOGY 
Over one-quarter of the global burden of cancer occurs within Europe despite the fact 
that Europes inhabitants comprise only approximately one-eighth of the worlds population. 
The major public health challenges led the European Commission in 1987 to establish a 
collaborative policy on cancer control. The Europe Against Cancer Program identified four 
separate areas (Eastern, Northern, Southern and Western Europe, figure 1) for action, namely 
data collection and research, information and health education, early detection and screening, 
and training and quality control (39). 
 
 
 
Figure 1. Areas of the Europe Against Cancer Program (39). 
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According to a worldwide study on cancer mortality, Eastern European men had the second 
highest rates of cancer (414.2), with extremely high rates in Hungary (566.6) and in the Czech 
Republic (480.5). The rates of cancer in Eastern European women were lower than in the 
other three areas, although as with men, female rates were very high in Hungary (357.2) and 
in the Czech Republic (333.6). Generally, mortality rates were highest in Eastern European 
countries, notably in Hungary, reflecting a combination of poorer cancer survival rates and a 
higher incidence of the more lethal neoplasms (39, 40 figure 2). 
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Figure 2. Cancer mortality rates in 1994 (40) 
 
 
By far the most common cancer in women in Europe is breast cancer. There were an 
estimated 321.000 new cases in 1995, representing over a quarter of all new cancers occurring 
in females. The most common primary tumor sites of women are breast (26%), colon and 
rectum (14%) and stomach (7%). There were approximately 124.000 deaths from breast 
cancer (17% of all female cancer deaths), and hence it was also the most common cause of 
cancer mortality in women (53). There are clear geographical differences in risk (figure 3) 
with high rates of incidence observed in Western Europe. It is likely that the different 
prevalence of the known risk factors for breast cancer between social classes explain much of 
the variation, while some of the excess incidence may be attributable to mammographic 
screening (39). 
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Figure 3. Breast cancer mortality rates in 1994 (54) 
 
According to the data of most countries of the world, except Asia, the incidence and mortality 
increases with age with the highest rate being among women over 85 where the incidence is 
over 350/100.000 (41). The risk of breast cancer development in women is one out of eight, 
which means that every eighth woman in the life period will have breast cancer. Breast cancer 
occurs 100 times more often in women than in men (42). 
Data from 1990 in the USA shows that in every 15th minute 4.28 new cases of breast cancer 
are registered and within the same period of time one woman dies from breast cancer. Black 
women have significantly lower incidence of breast cancer (maybe because of earlier and 
numerous deliveries), but higher mortality, probably due to the later detection, rarely positive 
hormonal receptors and worse socio-economical status, although molecular factors are not 
significantly different (43, 44). 
Considering the location in the breast, cancer occurs more often in the outer upper quadrant 
(38.5%) (figure 4) (35). 
 
 
 
Figure 4. Breast cancer frequency according to the location (35) 
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In Hungary in 1996, leading death cause of women aged 20-44 and 45-64 on second place 
behind deaths from cardiovascular diseases was cancerous diseases with 32.7% and 37.7% 
respectively (figure 5). Differently from the countries of the European Union, cancer 
mortality shows a continuous increasing tendency with no temporary decreases (45). 
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Figure 5. Mortality structure of women in Hungary, 1995 (45) 
 
At the beginning of the 70s, breast cancer incidence and mortality in Hungary was lower than 
the matching data from the countries of the European Union. Since then, statistics show a 
declining tendency, and the difference between Hungary and the European Union has already 
disappeared by the beginning of the 80s. Because of the efforts executed in the European 
Union, mortality has started to decrease in these countries, showing a continuous decreasing 
tendency even nowadays (figure 6) (46). In Hungary, continuous increase was observed in 
breast cancer mortality until the middle of the 90s. Since then, stagnation can be demonstrated 
(figure 7). According to a study executed in 2003, leading cause of cancerous death of 
Hungarian women is lung cancer, due to the increasing number of female smokers, not due to 
the decrease in breast cancer mortality (47). 
Prognosis of fully developed breast cancer is not among the worst ones and moreover, its 
relatively sensitive to different treatments. Indicators of survival show a continuous increasing 
in the last two decades (46), though Hungarian practice of mammography is far from 
considering the frequency of application. Also serious differences exist within the country, 
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which should be solved to make a progress in breast cancer screening with mammography, 
early diagnosis and prognosis (46). 
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Figure 6. Breast cancer mortality of women (aged 0-64 years) in Hungary 
and in the European Union, 1970-1999 (56) 
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Figure 7. Fatal breast cancer cases in Hungary, 1970-1999 (56) 
 
A national screening program of 10 years was initiated in 2001 in order to increse the 
efficiency of early diagnosis and to decrease the mortality of breast cancer. The screening 
rates of women aged 45-65 for 2001 and 2002 were 7% and 21.7%, respectively (figure 8) 
(48). According to an economics study, in the age group 45-65 with 10% mortality decline 
509 lives (Hungarian trend), with 20 mortality decline 1074 (English trend), while with 
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30% mortality decline 1582 lives (Swedish trend) could be saved during a 10 years 
screening programme (48). Despite the increasing trend of Hungarian women aged 45-65 
participating regulary the mammographic screening programmes (figure 8), only about 40% 
of them is enrolled in the screening, which is still far below the participating frequency of 
80% observed in Sweden (49), where a breast screening programme has successfully 
decreased the breast cancer mortality rate by 30% (48). Considering the above data, rate of 
Hungarian women aged 45-65 participating regular mammographic screening must be 
increased in order to decrease breast cancer mortality rate also on Hungary (48). 
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Figure 8. Estimated screening values of mammographic screening among women aged 45-65 
in Hungary, 2001-2002 (48) 
 
1.4. ETIOLOGY  
Etiological factors responsible for breast cancer development are still not completely 
known, but epidemiological evidences significantly suggest on three possible groups of 
genetic, endocrine and exogenous factors (50). 
Genetic mutations responsible for breast carcinogenesis are:  
1. activation of proto-oncogene (HER2/neu, located at 17q), 
2. inactivation (loss or mutation) of tumor suppressor genes: 1p, 1q, 3p, 5p, 6q, 7q, 
8p, 9q, 13q, 15q, 16q, 17p (p53), 17q (BRCA1 and NF1) and 18q 
3. inactivation of genes responsible for DNA repair (51-62). 
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Breast cancer family history is important for the first generation of female family members 
i.e. mother, daughter and sister. Women whose mothers had bilateral breast cancer before 
menopause carry the highest risk. They have nine times higher risk than others, i.e. 50% of 
them may develop breast malignancy (50). 
Endocrine factors are connected to the endogenous hyperestrogenism, and exogenous intake 
is connected to the intake of oral contraceptives (OC) and to hormone replacement therapy 
(HRT). The most important risk factors are: long period of generative time (earlier 
menstruation and later menopause), infertility, late age at first full-term pregnancy and obesity 
(63-66). 
Influence of physical exercise on the age of the first menstruation is very significant, e.g. girls 
who exercise regularly whether they practice ballet, swimming or running, start their period 
later than others. It was demonstrated that girls who did ballet started their menstruation at the 
average age of 15.4 years in comparison to the control group who started menstruation at the 
average age of 12.5 years (67). 
There are evidences that hyperestrogenism is connected to fibrocystic epithelial hyperplasia. 
Moderately increased (although disputed) risk is determined by exogenous estrogen (long 
usage of OC or HRT in menopause). Many studies have been published about the influence of 
OC and HRT on breast cancer, with controversial results and the only clear conclusion is that 
they have no protective effect against breast cancer (68-78). Breast cancer cells in women 
produce different growth factors (TGFα, PDGF). Estrogens stimulate the production of these 
growth factors and it is possible that interactions of circulating hormones, hormonal receptors 
of cancer cells and autocrine growth factors have a role in the progression of breast cancer. 
Measurement of the quantity of hormonal receptors in breast tissue is used to predict response 
of breast cancer cells to hormonal therapy (36). In the postmenopausal period larger source of 
estrogen is fat tissue, where conversion of adrenal androstendion into estrogen occurs (79). 
Women younger than 50 have little or no increased risk connected to the body mass (BM), 
while women over 60 with 10 kg overweight have an elevated risk (80%) of breast cancer 
development (80). Visceral obesity is common in over-weighted patients with breast cancer 
(81, 65, 79-83). 
Exogenous factors are connected to viral infections, higher consumption of alcohol, exposure 
to ionized radiation (natural and artificial), smoking, long term hair dying and stress (50, 44, 
84, 85). 
Virus, as an etiological factor of breast cancer, was incriminated in 1936 by Bittners 
discovery that a filterable agent, transmitted through mothers milk, causes breast cancer in 
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suckling mice. The virus, called mouse mammary tumor virus (MMTV), was later recognized 
as a retrovirus. There are some indications of the existence of a similar virus in human breast 
cancer, but research results are not convincible yet (44, 86). 
According to the numerous prospective studies, alcohol consuming increases the risk of breast 
cancer development (84). 
Selenium level in the sera of the patients with breast cancer is significantly lower than in 
healthy population (87). Consuming vitamin A, vegetables and fruits in an increased quantity 
decreases the risk (88). In the Mediterranean countries, the incidence is lower in women who 
regularly consume olive oil (89). 
Radiation exposure increases the risk of breast cancer development. For example, the 
hydrogen bomb thrown on Hiroshima and Nagasaki significantly increased incidence of 
breast cancer in that region after a latent period of 20 years. In other words, the highest 
incidence was noticed in women who were 10 to 14 years old in the moment of explosion and 
cancer was diagnosed most often when they were 30 to 49 years old (90). 
Certain number of patients connects trauma to the disease, but trauma could not be considered 
a possible risk of breast cancer development. It is quite possible that trauma is just a warning 
on already existing tumor (90). 
It is well known that the incidence of breast cancer in Japan or in China is 4 to 7 times lower 
than in the USA, but after few generations cancer incidence in Japanese and Chinese 
immigrants in the USA has become equal to that of the domicile population (91). Thus, 
international mortality in the period of 1983-1987 varied from less than 6 in Japan to almost 
30 in England and Wales (76). 
Psychiatric patients have 3.5 times higher incidence of breast cancer in comparison to other 
patients, i.e. 9.5 times higher in comparison to all the female population. It is not known yet 
whether stress caused by disease, medication therapy or something else is responsible for the 
increased risk seen in these patients (92). One of the exogenous predisposed factors in disease 
development is stress, however, as we find stress a hard subject to any kind of measurement, 
there are little information about it in the literature. 
On the other hand, there are a few cases of breast cancer where none of the aforementioned 
factors could be identified. 
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1.5. PATHOLOGY 
The breast is composed of epithelium, connective and fat tissue, so tumors developed 
in the breast are the tumors of these tissues, and can be benign or malignant. Most of the 
malignant breast tumors originate from the epithelium (41). 
There are several classifications of malignant breast tumors but two of them are used the 
most: classification according to the World Health Organization (WHO) (table 1) and 
classification according to the Armed Forces Institute of Pathology (AFIP) (table 2) (93, 94). 
Regarding the relationship of malignant cells to basal membrane, cancers can be noninvasive 
(cells do not invade the basal membrane) or invasive (cells do invade the basal membrane). 
The most common pathohistological type of breast cancer is the invasive ductal carcinoma 
(IDC) (>80% of all breast cancers) followed by the invasive lobular carcinoma (ILC) (10%) 
and medullary carcinoma (5%) which is less common at older age. Mucinous and papillary 
carcinomas are more common among older women, but make less than 10% of all breast 
cancers (41). 
 
 
A. Noninvasive B. Invasive (infiltrating) 
1. Intraductal carcinoma 
2. Intraductal papillary carcinoma 
3. Lobular carcinoma in situ 
1.   Invasive ductal carcinoma - not otherwise 
specified (IDC) 
2.   Invasive lobular carcinoma 
3.   Medullary carcinoma 
4.   Colloid carcinoma (mucinous carcinoma) 
5.   Pagets disease 
6.   Tubular carcinoma 
7.   Adenoid cystic carcinoma 
8.   Invasive comedo carcinoma 
9.   Apocrine carcinoma 
10. Invasive papillary carcinoma 
 
Table 1. WHO classification of breast cancer (95) 
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Epithelial cancers  
Non-invasive Intraductal carcinoma 
Intraductal carcinoma with Pagets disease 
Lobular carcinoma in situ 
Invasive Invasive ductal carcinoma 
Invasive ductal carcinoma with Pagets disease 
Invasive ductal carcinoma with predominant intraductal component 
Invasive lobular carcinoma 
Medullary carcinoma 
Mucinous carcinoma 
Invasive papillary carcinoma 
Tubular carcinoma 
Adenoid cystic carcinoma 
Secretory (juvenile) carcinoma 
Apocrine carcinoma 
Carcinoma with metaplasia 
Carcinoma with giant cells that are like osteoclasts 
Cystic hypersecretory carcinoma with invasion 
Carcinoma with endocrine differentiation 
Carcinoma rich with glycogen 
Carcinoma rich with lipids 
Invasive cribriform carcinoma 
Clinical types of cancer Inflammatory breast carcinoma 
Carcinoma during the pregnancy and lactation 
Occult carcinoma with metastases in the axillary lymphatic nodules 
Carcinoma of the ectopic breast 
Carcinoma in men 
Carcinoma in children 
Mixed cancers of the 
epithelium and of the 
connective tissue  
Malignant cystosarcoma phylloides 
Mesenchymal cancers Angiosarcoma 
Fibrosarcoma 
Leiomyosarcoma 
Chondrosarcoma 
Osteosarcoma 
Haemangioperycitoma 
Dermatofibrosarcoma protuberans 
Cancers of the breast 
skin 
Melanoma of the nipple 
Carcinoma of the squamous cells of the nipple 
Carcinoma of the basal cells of the nipple 
Carcinoma of the skin 
Cancers of the 
lymphatic and 
hemopoetic tissue 
Non-Hodgkin lymphoma 
Plasmacytoma 
Leukemical infiltration 
Hodgkin disease 
 
Table 2. AFIP classification of malignant breast tumors modified according to Rosen (93, 94). 
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Histopathological grading of breast cancer according to Blom-Richardson is also important to 
mention. It shows the way of growth of IDC and the cytological characteristics of 
differentiation (table 3) (95, 96). 
 
Grading parameters  
a) Formation of the gland 
tubules and acini 
1 point: characteristic formation of tubules (>75%) 
2 points: moderate formation of tubules (10-75%) 
3 points: little or without tubules at all (<10%) 
b) Pleiomorphism of cancer 
cells nucleus (abnormality in 
size, shape and structure) 
1 point: isomorphism of nuclei 
2 points: moderate variability in size, shape and in 
structure of nucleus 
3 points: characteristic polymorphism 
c) Mitoses / 10 hpf 1 point; < 9 mitosis 
2 points; 10-19 mitosis 
3 points; > 20 mitosis 
 
After summing the points of all parameters the level of differentiation can be 
determined according to the following scheme: 
 
G1 (3-5 points) well differentiated 
G2 (6-7 points) moderately differentiated 
G3 (8-9 points) poorly differentiated 
 
Table 3. Histopathological grading of IDC according to Blom-Richardson  Elstons 
modification (95, 96) 
 
Ductal carcinoma is the most common and most aggressive form of breast cancer. According 
to certain authors it makes 90% of all beforehand-undiscovered cases found by 
mammography. It becomes invasive very often, usually in half the time period than lobular: it 
takes 20 years for the intralobular form to become invasive, while for ductal carcinoma it 
takes only 10 years. Ductal cancers are divided into subtypes: comedocarcinoma, cribriform, 
apocrine, papillary, micropapillary and solid type. Comedo and cribriform types are the most 
aggressive ones (41). 
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Lobular carcinoma represents 11% of all breast cancers. Its characteristic is the bilateral 
manifestation, whether at the same time or in one breast after another. 
IDC is the most common type of breast cancer (>80% of all breast carcinomas). The cancer is 
obviously invasive even macroscopically and invades connective tissue stroma. Small foci of 
calcifications are often evident on the cut surface. It could cause retraction of the skin and/or 
the nipple and fixation to the underlying chest wall. Histologically, connective stroma can be 
seen with focuses or rays of tumor cells scattered about. At the edges of the tumor, malignant 
cells infiltrate surrounding tissue, very often invading perivascular and perineural spaces as 
well as lymphatic and blood vessels (figure 9) (97). 
 
 
 
Figure 9. Invasive ductal carcinoma of the breast (97) 
 
Tubular carcinoma or well-differentiated adenocarcinoma is diagnosed in 10 to 20% of the 
breast cancer cases and it can be relatively easily discovered by mammography. 
Macroscopically, tubular cancer is usually a small lesion, often smaller than 1 cm. 
Histologically, areas of sclerosis or deposits of elastin can be seen. Tubular cancer is often 
combined with intraductal cancer (65% of the cases). Tumor cells are often atypical and show 
numerous mitoses. About 10% of tubular cancers are metastatic. (figure 10) (41). 
 
 
 
Figure 10. Tubular carcinoma of the breast (97) 
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Lobular carcinoma is developed from one or more terminal ducts and/or from ductules (acini). 
It often appears bilaterally (20%). Two types are described: lobular cancer in situ and 
intralobular carcinoma. In the first type cells are bigger than normal, with oval or round nuclei 
and small nucleoli, neither mitoses nor polymorphism can usually be found. Dilatation of the 
acinus is characteristic for intralobular carcinoma. About 30% of patients develop a second 
malignancy in the same or in the other breast, and the developed infiltrating carcinomas can 
be either lobular or ductal. Intralobular cancer makes 5 to 10% of all the breast carcinoma 
cases. Macroscopically, lobular carcinoma is poorly edged and usually of rubber consistency, 
sometimes hard and scirrhous. Histologically, cancer cells are mostly small and uniformed 
with small rate of polymorphism (figure 11) (41) 
 
 
 
Figure 11. Invasive lobular carcinoma of the breast (97) 
 
Medullary carcinoma represents about 1% of all the breast cancers. It is rather soft and fleshy 
than hard on external palpation. Histologically, the carcinoma is characterized by solid, 
syncytium-like sheet of large cells that are mainly undifferentiated, although sometimes are 
well differentiated. Lymphatic infiltration is a common finding (figure 12) (41). 
 
 
 
Figure 12. Medullary carcinoma of the breast (97) 
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Colloid or mucinous carcinoma (carcinoma colloides seu mucinosum) is characterized by 
intracellular and extracellular mucinous formation. Macroscopically, colloid carcinoma is 
consisted of tender and extensive gray-blue nodules of gelatinous consistency. Histologically, 
there are two forms of tumor: 1) cancer cells are visible as small islands or even as isolated 
cells that float in great lakes of mucine, which leaks into the surrounding tissue space, 2) cells 
grow in well-presented gland formations. In both forms, tumor cells can be vacuolated by the 
mucine content (figure 13) (41). 
 
 
Figure 13. Colloid/mucinous carcinoma of the breast (97) 
 
Pagets disease (morbus Paget) is a special type of ductal carcinoma, affecting women of 
older age. Development of the disease starts as typical intraductal cancer that arises from the 
main excretory ducts of the breast and extends intraepithelially to involve the skin of the 
nipple and the areola. The affected skin is frequently fissured, ulcerated and oozing. 
Surrounding inflammatory hyperemia, edema and also bacterial infections are often found. 
The histologic hallmark of this tumor is invasion of the epidermis with characteristic tumor 
cells called Pagets cells. These cells are large and hyperchromatic, surrounded with a lightly 
stained ring that represents intracellular deposit of mucopolysaccharides. The morphologic 
picture is similar to that of the intraductal carcinoma, but this type of cancer has better 
prognosis (figure 14) (41). 
 
 
 
Figure 14. Pagets disease (97) 
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1.6. CLINICAL DIAGNOSIS  
Main diagnostic methods for detection of breast cancer are anamnesis, physical 
examination and mammography. However, a biopsy for pathological evaluation should be 
performed for exact diagnosis in every case. Different techniques are used to obtain 
pathological material, but two of them are mostly used: 1) cytological evaluation of the breast 
discharge i.e. of the aspirated material from the breast, 2) intra-operative biopsy with 
histological evaluation of the frozen section. The first method is suitable for diagnosis, the 
second one is extremely valuable in selecting treatment for breast cancer depending on 
histological verification of the relationship of malignant cells towards basal membrane, in 
other words, whether the cancer is invasive or non-invasive. 
Indirect diagnostic methods are self-examination (harmless, easy to learn, free of charge), 
anamnesis, physical examination, native mammography, ultrasound and new diagnostic 
techniques such as MRI (Magnetic Resonance Imaging), digital mammography, CAD 
(computer-aided diagnosis), PET (positron emission tomography), SPECT (single photon 
emission imaging and computed tomography), thermography, diaphanoscopy and use of 
molecular markers (98).  
Anamnesis is consisted of two parts:  
• Family history: informs about any illness and causes of death in the family of the 
patient, with emphasis on the breast diseases of female relatives (grandmother, 
mother, aunts and sisters of patient). 
• Personal history: provides information about the age of menarche, the beginning of 
sex life, age at first delivery, number of deliveries, age of menopause. The patient 
should also be asked whether she performs breast self-examination, has noticed any 
change in her breast, about the number and intervals of previous physical breast 
examinations, previous diagnostic procedures of the breast, usage of OC and HRT.  
Physical breast examination should be done both in sitting and supine positions. A thorough 
physical breast examination should be done to locate any lump or suspicious area. The skin of 
the breast and the nipples should also be carefully inspected. It is important to notice any 
discharge from the nipple. The lymph nodes under the armpit should be palpated too. 
Although, by this examination it is possible to discover only lumps greater than 1 cm, its 
importance is very emphasized, especially when combined with mammography due to its 
importance as a complementary examination method (98). Sometimes, ultrasound can give 
dubious results although the result of mammography is negative (99). Sensitivity of 
mammography, ultrasound and palpation is shown in figure 15 (99). 
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Figure 15. Sensitivity of palpation, ultrasound and mammography 
in detecting breast cancer (99) 
 
Mammography and ultrasound of breast 
Ultrasound (after physical examination) is an important diagnostic technique usually applied 
in the population of younger women (figure 16), due to its sensitivity and specificity that is 
higher in this period compared to mammography (figure 17), because the largest part of the 
breast in the generative age is made of hyperechogen gland tissue, while in the menopause 
gland tissue is replaced with hypoechogen fat tissue (99). 
 
 
 
 
Figure 16. Ultrasonography  ductal mammary carcinoma 
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Figure 17. Mammography 
 
In elderlies, methods are complementary, but since mammography is easier to perform and 
adequately sensitive, it is preferred to ultrasound in this population. In order to decrease the 
number of unnecessary biopsies, each suspicious change should be verified by cytopunction. 
Moreover, certain number of breast cancers can not be discovered by mammography, 10-25% 
of the palpable breast cancers are not visible by mammography, and patients discover an 
additional 20-25% in the period between mammographic and clinical controls (100). 
Molecular markers of breast cancer are normally existing compounds of the body, and are 
found in higher concentration in patients with breast cancer than in healthy women. The level 
of the carcino-embryonic antigen (CEA) is increased by a few percentages in stage I and II 
breast cancers. Though CA15-3 and CA549 markers are elevated in 20% to 50% of patients 
with primary breast cancer, they can also be found in a higher concentration in 20% of 
patients with benign breast lesions and with gastrointestinal diseases. Cathepsin D could be 
more important in diagnostic testing due to its specificity in breast cancer. But none of these 
markers are specific only for breast cancer, and could even in combination imply to early 
stage of the breast cancer. In order to propose an appropriate diagnosis of breast cancer and to 
observe treatment success, elementary laboratory techniques such as sedimentation, total 
blood exam, biochemical examination (SGOT, SGPT, γGT, ALP with isoenzymes, LDH) are 
needed. X-ray of lung for detecting possible metastases is compulsory before any therapeutic 
treatment (101-104). 
 
1.7. CLASSIFICATION 
1.7.1. TNM CLASSIFICATION 
Besides histopathological features, the clinical stage of the tumor is also considered an 
important factor in determining prognosis and proper treatment. Pierre Denoix developed the 
basic classification of the malignant tumors according to their dissemination (1943-1953). He 
took tumor seize (T), tumor dissemination to regional lymph nodes (N), and presence of 
metastasis (M) into consideration in his classification system, named TNM system. Today, 
 25
staging of cancer is determined by the UICC (Union International Contre le Cancer) 
classification based on the TNM system (table 4). It was changed in 1987 to bring UICCs 
and AJCCs (American Joining Commission on Cancer Staging and End Results Reporting) 
classifications closer to each other. The final classification system is a result of clinical, 
radiological and laboratory investigations (44). 
 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ(DCIS: ductal carcinoma in situ, LCIS: lobular carcinoma in situ, 
Pagets disease of the nipple with no tumor 
T1 Tumor 2 cm or less in greatest dimension 
T1mic Microinvasion 0.1 cm or less in greatest dimension 
T1a Tumor more than 0.1 cm but not more than 0.5 cm in greatest dimension 
T1b Tumor more than 0.5 cm but not more than 1 cm in greatest dimension 
T1c Tumor more than 1 cm but not more than 2 cm in greatest dimension 
T2 Tumor more than 2 cm but not more than 5 cm in greatest dimension 
T3 Tumor more than 5 cm in greatest dimension 
T4 Tumor of any size with direct extension to chest wall or skin, only as described below 
T4a Extension to chest wall, not including pectoralis muscle 
T4b Edema (including peau dorange) or ulceration of the skin of the breast or satellite 
skin nodules confined to the same breast 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Nx Regional lymph node metastasis cannot be assessed (e.g., previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis to movable ipsilateral axillary node(s) 
N2 Metastasis to ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent 
ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph 
node metastasis 
N2a Metastases in ipsilateral axillary lymph nodes fixed to one another (matted) or to 
other structures 
N2b Metastasis only in clinically apparent ipsilateral internal mammary nodes and in the 
absence of clinically evident axillary lymph node metastasis 
N3 Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary lymph 
node involvement, or in clinically apparent ipsilateral internal mammary lymph 
node(s) and in the presence of clinically evident axillary lymph node metastasis; or 
metastasis in ipsilateral supraclavicular lymph node(s) with or withour axillary or 
internal mammary lymph node involvement 
N3a Metastasis in ipsilateral infraclavicular lymph node(s) 
N3b Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary lymph 
node involvement, or in clinically apparent ipsilateral internal mammary lymph nodes  
the persence of clinically evident axillary lymph node metastasis; no metastasis in 
ipsilateral supraclavicular lymph nodes with or without axillary or internal mammary 
lymph node involvement 
N3c Metastasis in ipsilateral supraclavicular lymph node(s) 
Mx Distant metastases cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis  
 
Table 4. TNM breast cancer classification (44) 
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1.7.2. STAGING 
Staging refers to the grouping of patients according to the extent of their disease. 
Staging is important to determine treatment for individual patients, estimate their prognosis 
and compare the results of different treatment programs (table 5 and figure 18) (100, 105). 
 
 T (tumor) N (nodes) M (metastases) 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
Stage IIIB T4 N0 M0 
 T4 N1  
 T4 N2  
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
 
Table 5. Staging of breast cancer (100, 105) 
 
 
 
Figure 18. Staging of breast cancer 
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1.8. DIFFERENTIAL DIAGNOSIS 
There is an important principle that each suspicious change in the breast must be 
considered as a malignant tumor until proved differently. This principle imposes biopsy of all 
the lesions. It is prudent to pay attention to some of the lesions that appear more often at 
certain age in women. Cystic hyperplasia, fibroadenoma and mastitis occur more often before 
the age of 35. Most tumors of the breast develop between ages 40 and 60. Incidence of breast 
cancer is growing with the age. 
 
1.9. TREATMENT 
Breast cancer treatment is done according to different protocols depending on the 
histological type of the tumor, stage of the malignant process and the overall physical 
condition of the patient. Different combinations of surgical treatment, radiotherapy, 
chemotherapy, hormonal therapy and immunotherapy are in use. In most cases treatment 
begins with surgery. Nowadays, radical mastectomies according to Halsted and superradical 
interventions with thoracotomy are replaced with breast-conserving surgery like 
quadrantectomy. In patients with histological signs of invasive breast cancer, besides surgery 
and irradiation, systemic therapy is often used in order to prevent relapses. 
 
1.10. PROGNOSIS 
Some of the prognostic factors, like tumor size, histological differentiation are reliably 
approved, while reliability of others still needs to be approved. According to histological 
classification, invasive ductal carcinoma is the most malignant lesion, followed by invasive 
lobular carcinoma. Medullary and mucinous carcinoma usually have better prognosis. 
It is known that tumor development, as well as prognosis, depends on histological 
differentiation. Well-differentiated tumors develop slower and metastize later. Poorly 
differentiated tumors are more malignant, anaplastic tumors being the worst. An 
inflammatory cell reaction composed of lymphocytes and/or plasma cells in tumor stroma and 
around metastases is a good prognostic factor. 
The Breast Cancer Detection Demonstration Project study demonstrated that survival rate 
depends not only on the clinical stage of disease but also on patients age (figure 19 and 20) 
(106, 107). 
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Figure 19. Survival by stage at diagnosis among women aged 40-49 at diagnosis (106) 
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Figure 20. Survival by stage at diagnosis among women aged 50-59 at diagnosis (107) 
 
 
The 5-year disease free survival (DFS) for patients with localized and properly cured breast 
cancer is 98%, and 95% after 10 years, whereas patients with metastasis have 30% DFS and 
50% after 10 years (107).  
Recently, breast cancer research is mainly related to molecular biology. Some of the new 
insights are shown below: 
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Patient age (35, 44, 50, 85, 107) 
Obesity (35, 44, 66, 80) 
Relationship of tumor and basal membrane (35) 
Size of the primary tumor (35, 44) 
Histological type of tumor (35, 41, 44) 
Histological differentiation of tumor (35, 44, 105) 
Proliferating ability of tumor cells (mitotic index, index of cells 
labeled with 3H thymidine-LI) (35, 44) 
Characteristics of the inflammatory reactions in the tumor (35, 44) 
Presence of blood vessels invasion (35, 44) 
Status of lymph nodes (number, localization and size of positive 
lymph nodes) (35, 44, 103) 
Metastases and their locations (35, 44) 
Expression of the estrogen and progesterone receptors (64) 
Ploidy / DNA index (56, 71) 
Proliferating cell nuclear antigen / PCNA (35) 
Proliferation marker MB-1 (35) 
Expression of HER2/neu oncogene (44) 
Expression of tumor suppressor gene p53 (3, 4, 5) 
Expression of tumor suppressor gene MMP2 (35) 
Expression of tumor suppressor gene nm23 (44) 
Expression of receptors for EGFR (145, 146) 
Expression of laminine receptors (LR) (35) 
Srp-27 protein expression (57) 
Cathepsin D expression (57) 
Level of the 5-hydroxymetil-2-deoxyuridin UDNA (57) 
 
 
1.11. SCREENING 
Because of the connection between early detection and improved outcome, proper 
screening method is the main goal in breast cancer cases. Many studies have demonstrated 
that screening of breast cancer is evidently useful for women aged 50 to 74, but it is under 
debate for women aged 49 and younger (108-110). Methods of early detection are self-
examination, physical examination, ultrasound and mammography (38). 
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The best guidelines for early detection of breast cancer are shown in figure 18. Women aged 
20 or older should perform breast self-examination every month. Over age 35, women should 
have a breast examination performed by health professionals every year, women should have 
baseline mammography at age 40 or even earlier if they are in a high-risk category (after age 
35). Mammography should be repeated every two years and every year for women aged 50 
(110). Regular mammograms (figure 21) can decrease breast cancer mortality of women aged 
50 to 69 years by 30% (110). 
 
 
Figure 21. Guidelines for early detection of breast cancer 
 
 
2. MATERIALS AND METHODS 
2.1. Tissue samples 
Seventy-two BC specimens, 72 autologous PTT sampled at 1 cm, 65 at 2 cm and 43 at 
3 cm from the primary BC and 44 mammary BL were prospectively collected for 
immunohistochemical analysis (IHC) and fluorescent in situ hybridization (FISH) from 
patients surgically treated at Regina Elena Cancer Institute. 
Further hundred and eighty-six patients receiving anthracycline-based adjuvant therapy were 
selected for studying the COX2, hormone receptors, HER2, p53, Ki67, Fas, FasL, PGE2S and 
EGFR expression in primary breast cancers and in the their autologous lymph node 
metastases. 
 
2.2. Immunohistochemistry 
IHC staining was carried out on 5 µm thick sections on silane (APES, Sigma, St. 
Louis, MO, USA) treated slides for routinely fixed paraffin embedded blocks. The 
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deparaffinized and rehydrated sections were pretreated twice in microwave oven at 750 W for 
5 min in citrate buffer pH=6 and incubated for 60 min. at room temperature with primary 
antibodies. The reaction was visualized using a streptavidin-biotin immunoperoxidase system 
(LSAB2 kit, DakoCytomaton, Milan, Italy) and 3-amino-9-ethyl-carbazole solution 
(DakoCytomaton) as chromogenic substrate. Sections were then slightly counterstained with 
Mayers haematoxylin and mounted in aqueous mounting medium (Glycergel, 
Dakocytomaton). 
Antibodies and working solutions used for immunohistochemistry are shown in table 6. 
Overexpression of HER2 oncogene product was determined using the high affinity 
monoclonal antibody (mAb) 300G9 recognizing an epitope of the gp185erbB-2 extracellular 
domain not cross-reacting with EGFR (111) and mAb CB11, which recognizes a peptide of 
the intracellular domain of the receptor (BioGenex, Menarini, Italy). To verify the benign 
nature of 1 cm PTT, smooth muscle actin staining was performed with using monoclonal 
mouse anti-human anti-actin (smooth muscle) antibody 1A4 (DakoCytomation). p53 protein 
expression was evaluated using the murine mAb DO7 (DakoCytomation). Fas protein was 
detected by using a commercial mAb (Novocastra) raised against a peptide corresponding to 
amino acids 316-335, mapping at the carboxy terminus of human Fas. FasL expression was 
evaluated using N-20 mAb (Novocastra), which recognizes epitopes corresponding to amino 
acids 2-19 mapping at the amino terminus of the human protein. Estrogen (ER) and 
progesterone (PgR) receptors were assayed with using commercially available antibodies 
(ER1D5 and 1A6 Immunotech, UCS, Rome, Italy). To assess the proliferative activity of the 
tumors, immunostaining with monoclonal antibody Mib-1 (DakoCytomation) was performed. 
For COX2 investigations antigen was retrieved using microwave (two cycles of 750W, 5 min 
in citrate buffer) and sections were incubated for 60 min at room temperature with COX2-
specific human polyclonal primary antibody (125 ng/µl, 160107, Cayman Chemical Co., Ann 
Arbor, MI, USA). The reaction was visualized using a streptavidin-biotin immunoperoxidase 
and chromogenic substrate system (Histostain-Plus, Broad Spectrum (DAB), 85-9643, 
ZYMED Laboratories Inc., CA, USA). PGE2S immunohistochemistry was performed with a 
PGE2S-specific rabbit polyclonal primary antibody (125 ng/µl, 160140, Cayman Chemical 
Co., Ann Arbor, MI, USA) while EGFR activity was examined with a commercial mouse 
primary antibody (750 ng/µl, 28-0005, ZYMED Laboratories Inc., CA, USA). In case of 
EGFR antigen was retrieved using pepsine (Digest-All 3 ready-to-use pepsine solution, 00-
3009, ZYMED Laboratories Inc., CA, USA) for 10 min. at 37°C, otherwise the reactions were 
performed both for PGE2S and EGFR as described for COX2 immunoreaction. 
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Antibody Working 
solution 
Origin 
HER2 300G9 1:200 BioGenex, Menarini, Italy 
HER2 CB11 1:200 BioGenex, Menarini, Italy 
Actin 1A4 1:300 DakoCytomaton, Milan, Italy 
p53 D07 1.300 DakoCytomaton, Milan, Italy 
Fas (CD95) 1:50 Novocastra Laboratories Ltd., Milan, Italy 
FasL 1:50 Novocastra Laboratories Ltd., Milan, Italy 
ER ER1D5 1:300 Immunotech, UCS, Rome, Italy 
PgR 1A6 1:300 Immunotech, UCS, Rome, Italy 
Mib-1 1:300 DakoCytomaton, Milan, Italy 
COX2 1:200 Cayman Chemical Co., Ann Arbor, MI, USA 
PGE2S 1:200 Cayman Chemical Co., Ann Arbor, MI, USA 
EGFR 1:200 ZYMED Laboratories Inc., CA, USA 
 
Table 6. Antibodies used for immunohistochemistry 
 
Immunostained slides were analyzed and scored independently by 2 investigators. For HER2 
staining in tumors the score was defined as 3+/2+ when more than 10% of the neoplastic cells 
displayed strong plasmamembrane immunoreactivity, 1+ when <10% of the cells displayed 
weak positive reaction and negative when no stain was observed. 
In the case of p53, immunoreactivity was considered positive when a distinct nuclear stain 
was observed in at least 10% of the tumor cell population. Since patterns of p53 reactivity in 
benign lesions and PTT samples may differ from those in breast cancers, the case was scored 
positive even if scattered nuclei were positive. 
As in regard of Fas and FasL, benign and malignant tissues displayed the following two 
patterns of immunoreactivity: 1) a cell membrane staining associated with a granular 
cytoplasmic reactivity, and 2) a diffuse cytoplasmic staining of variable intensity. Specimens 
with a faint, and/or questionable cytoplasmic staining were scored negative. Immunostaining 
was scored as follows: negative (no expression), heterogenous (expression in 10-50% of the 
cells) and homogenous (expression in >50% of the cells). Fas and FasL staining patterns in 
benign lesions and PTT samples were not different from those observed in tumor samples, 
therefore the same scoring criteria were used. 
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The following criteria were agreed upon for COX2 before the analysis: 0: no staining, 1+: 
weak diffuse cytoplasmic staining (may contain stronger intensity in less than 10% of the 
malignant cells), 2+: moderate to strong granular cytoplasmic staining in 10-90% of the 
cancer cells, 3+: over 90% of the tumor cells stained with strong intensity (112). For further 
analysis COX2 immunostaining in the investigated cases was considered only positive or 
negative. 
Regarding Ki67 staining, for each section, 5x102 tumor cells in 4 random fields were counted 
to determine the percentage of Ki67 positive nuclei. Ki67 index was classified high when 
>30% (median value). 
ER, PgR, PGE2S and EGFR staining was each considered positive when ≥10% of the cells 
showed immunoreactivity. In case of less or no positive cells reaction was considered 
negative. 
 
2.3. FISH 
PathVysion HER2 DNA Probe Kit (Abbott Diagnostici, Rome, Italy) was used to 
determine the HER2 DNA amplification in breast cancer and PTT samples. The LSI HER2 
(Spectrum Orange) probe (Abbott Diagnostici, Rome, Italy) contains DNA sequences specific 
for the HER2 human gene locus and hybridizes to 17q11.2-q12 region of human chromosome 
17. The CEP17 (chromosome enumeration probe, Spectrum Green) probe (Abbott 
Diagnostici, Rome, Italy) contains alpha-satellite DNA that hybridizes to the D17Z1 locus. 
These two probes were premixed and pre-denatured. CEP17 was used as a control to 
determine copy number of chromosome 17 in order to adjust for the effect of aneuploid 
chromosome 17 when the HER2 copy numbers were counted. The ratios of average copy 
numbers per cell were calculated to establish the presence of amplified HER2. After 
pretreatment, the procedure Hybrite System (Vysis, Abbott Diagnostici, Rome, Italy) was 
used. Hybrite is an open system for hands-free denaturation and hybridization when using in 
situ DNA probe procedure. After overnight hybridization at 37 °C, post-hybridization wash 
was applied using 2xSSC/NP40 (Abbott Diagnostici, Rome, Italy) at 73°C. Tissue sections 
were counterstained with DAPI (4,6-diamidino-2-phenylindole, Abbott Diagnostici, Rome, 
Italy). The slides were processed with Olympus BX60 fluorescence microscope (Olympus 
Italia, Segrati, Italy) equipped with a 100-watt mercury lamp. Separate band pass filters were 
used for the detection of the HER2 probe signals (Spectrum Orange), CEP 17 probe signals 
(Spectrum Green) and DAPI counter stain. Fluorochrome signals were captured individually 
and images were generated via computer with Quips Genetic Workstations and Imaging 
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Software (Vysis, Abbott Diagnostici, Rome, Italy). The slides were observed at 1000x 
magnification. At least 100 well-defined nuclei were scored for each hybridization processes. 
Clumps, overlapping nuclei and tumor infiltrating leucocytes were disregarded. Only nuclei 
with unambiguous chromosome 17 centromeric hybridization signals were scored for the 
HER2 signal numbers. The amplification was defined as a HER2 to CEP 17 ratio >2. 
 
2.4. Statistical analysis 
Association between clinical and biopathological variables were evaluated using the 
chi-square test. All these parameters were treated as dichotomous or categorical variables and 
described using the Pearson statistics. The disease-free (DFS) and overall survival (OS) 
curves were estimated by the Kaplan-Meier product-limit method. Log-rank test was used to 
assess differences between subgroups. Significance was defined at the p<0.05 level. The 
relative risk and the confidence limits were estimated for each variable using the Cox 
univariate model and adopting the most suitable prognostic category as reference group. A 
multivariate Cox proportional hazard model was also developed using stepwise regression 
(backward selection) with predictive variables which were significant in the univariate 
analyses. Enter limit and remove limit were p=0.10 and p=0.15 respectively. All analyses 
were conducted using the BMDP software package (Chicago, IL). 
 
 
 
3. RESULTS 
3.1. Morphological features of peritumoral tissues and benign breast lesions 
The 72 breast cancer patients selected for the PTT studies had a mean age of 51.6 
years (range 36-88), including pre- and postmenopausal women. Of the 72 breast carcinomas, 
according to AFIP classification, 62 were diagnosed as infiltrating ductal carcinomas and 10 
as infiltrating lobular carcinomas. Tumor sizes varied from T1 to T3, (T1 in 39 cases, T2 in 31 
cases and T3 in 2 cases). Forty-one of the patients were node negative while 31 tumors had 
associated nodal metastases. Estrogen receptor positivity was found in 48 cases and 
progesterone receptors were detected in 49 tumors. Nineteen malignant lesions overexpressed 
HER2 and 32 proved to be p53 positive. Fas positivity occurred in 31 cases whereas 39 
carcinomas showed strong FasL reactivity (table 7). 
The histopathological features of the 72 PTT sampled at 1, 2 and 3 cm from the autologous 
BC to determine HER2, p53, Fas and FasL expression are summarized in table 8. Fibrocystic 
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changes (FC) were variably associated to florid and/or sclerosing adenosis (FA+SA), 
papillomatosis (PM), apocrine metaplasia (AM), typical ductal hyperplasia (TDH) and 
atypical ductal hyperplasia (ADH) in 57 specimens collected at 1 cm, in 50 at 2 cm and in 35 
at 3 cm from the autologous BC. 23 BL displayed the same morphological features. 
TDH+ADH combined to FA were found in 5 PTT at 1cm, in 5 at 2 cm, and in 3 at 3 cm 
whereas none of the benign tumors presented these combinations of morphological changes. 
TDH was associated to AM, SA, PM in 10 PTT closest to the autologous BC, in 10 and in 5 
PTT sampled at 2 and 3 cm respectively. Only two benign tumors displayed these 
histopathological aspects. In addition, 19 fibroadenomas (FBA),4 of which combined with 
FA, were diagnosed. 
 
Characteristics Total number of patients = 72 
 No % 
Age = 51.6 (range 36-88) - - 
Tumoral histotype 
Infiltrating Ductal Carcinoma 
Infiltrating Lobular Carcinoma 
 
62 
10 
 
86.1 
13.9 
Tumor size 
T1 
T2 
T3 
 
39 
31 
  2 
 
54.1 
43.1 
  2.8 
Nodal Status 
No 
N1 
 
41 
31 
 
56.9 
43.1 
ER (cut off > 10%) 
Positive 
Negative 
 
48 
24 
 
66.6 
33.4 
PgR (cut off > 10%) 
Positive 
Negative 
 
49 
23 
 
68.1 
31.9 
HER2o 
Positive 
Negative 
 
19 
53 
 
26.3 
73.6 
P53* (cut off > 10%) 
Positive 
Negative 
 
32 
40 
 
44.4 
55.6 
Fas 
Positive 
Negative 
 
31 
41 
 
43.1 
56.9 
FasL 
Positive 
Negative 
 
39 
33 
 
54.2 
45.8 
 
Table 7. Clinicopathological and biologic characteristics of 72 breast cancer patients 
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 1 cm PTT 2 cm PTT 3 cm PTT Benign lesions
FC + FA and/or SA 41 35 27 18 
FC + PM + SA + AM + FA 1 0 1 3 
FC + TDH + AM 10 8 6 0 
FC + ADH + FA + PM 3 4 1 1 
FC + AM + SA 2 3 0 1 
TDH + ADH +FA 5 5 3 0 
TDH + AM + SA + PM 10 10 5 2 
FBA 0 0 0 15 
FBA + FA 0 0 0 4 
Total 72 65 43 44 
 
Table 8. Pathological features of multiple peritumoral tissues and benign lesions 
 
3.2. HER2 and p53 expression in breast cancers, multiple PTT and benign mammary 
lesions 
As summarized in table 9, we evaluated HER2 and p53 expression in 44 benign 
tumors, 72 cancers and the corresponding PTT sampled at 1 cm (72 cases), 2 cm (65 cases) 
and 3 cm (43 cases) respectively from the autologous BC. Of the 44 benign lesions (4.5%), 2 
were HER2 positive showing a 2+ immunostaining clearly restricted to the cell membrane. 
HER2 overexpression was mainly found in FA and hyperplasic areas. 
Nineteen of the 72 breast cancer samples (26.3%) were HER2 positive (2+/3+ score). In 10 
PTT independently of the distance from the primary tumor we observed a distinct cell 
membrane immunostaining prevalently confined to TDH, ADH and FA. In these PTT we 
never found a 3+ score immunostaining whereas a weak 1+ score staining was observed in 9 
PTT (12.5%) collected at 1 cm, 6 at 2 cm (9.2%) and 5 at 3 cm (11.6%). 
The percentage of HER2 overexpression was significantly higher in malignant tumor than in 
benign lesions (p=0.007) and PTT sampled at 1, 2 and 3 cm (p=0.01, p=0.001 and p= 0.03 
respectively). No difference in HER2 overexpression was observed among the three PTT 
analyzed by IHC (p=0.49, p=0.99 and p=0.99 respectively). HER2 immunostaining in tumor 
and PTT samples are shown in figure 22A and 22B. Smooth muscle actin staining was also 
performed to verify differentiation of BC and PTT (figure 23A and 23B). 
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  HER2  P53 HER2 + p53 
 1+ (%) 2+ (%) 3+(%) 
Positive cases 
(%) 
Positive cases 
(%) 
      
Benign lesions      
44 patients 5 (11.4) 2 (4.5) 0 (0.0) 3 (6.8) 1(2.2) 
      
Breast cancers      
72 patients 9 (12.5) 11 (15.3) 8 (11.1) 34 (47.2) 12 (16.6) 
      
PTT 1 cm      
72 patients 9 (12.5) 5 (6.9) 0 (0.0) 5 (6.9) 4 (5.5) 
      
PTT 2 cm      
65 patients 6 (9.2) 3 (4.6) 0 (0.0) 1 (1.5) 1 (1.5) 
      
PTT 3 cm      
43 patients 5 (11.6) 2 (4.6) 0 (0.0) 1 (2.3) 0 
 
Table 9. Evaluation of the HER2 and p53 expression in 44 benign mammary lesions, 72 
breast cancer and autologous peritumoral tissues 
 
 
 
 
Figure 22. HER2 positivity in breast cancer (A) and PTT sample (B) 
 
A B 
 38
 
Figure 23. Loss of myoepithelial cells in the invasive carcinoma (C) and maintenance of 
myoepithelial cells (D) in the correspondent PTT 
 
Thirty-four BC (47.2%) were p53 positive (figure 24A) with variable percentage of nuclear 
staining ranging from 10% to 90% with a median value of 40%. In contrast we observed p53 
nuclear accumulation in only 1 benign lesion. Also in PTT, p53 positivity was seen in a 
limited number of lesions (figure 24B). 4 cases of TDH and 3 FA displayed p53 nuclear 
accumulation in a low percentage of epithelial cells ranging from 1% to 10%. 
p53 expression was higher in malignant tumors with respect to benign lesions (p<0.001) and 
in malignant tumors versus 1, 2 and 3 cm PTT (p<0.0001). No significant difference in p53 
positivity was observed among the three PTT (p=0.21, p=0.42 and p=0.99 respectively). 
 
 
 
Figure 24. p53 immunostaining in breast cancer (A) and PTT sample (B) 
 
A concomitant expression of HER2 and p53 was detected in 1 benign lesion (TDH), 12 BC 
and 5 PTT (3 FA, 1 TDH and 1 ADH), 4 of which were collected at 1 cm from autologous BC 
and 1 at 3 cm. 
A 
B A 
A B 
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In order to verify whether in PTT HER2 overexpression, detected by the means of IHC 
methods, was correlated to gene amplification, we submitted to FISH analysis the 10 PTT 
immunohistochemically positive for HER2 (figure 25). Table 10 shows that 5 (2 FA, 3 TDH) 
out of the 10 PTT demonstrated HER2 gene amplification (ratio >2). In the autologous BC 
HER2 was amplified in 7 of these 10 cases. 
 
 Histotype HER2 status 
 Tumor 
 
PTT Tumor 
FISH      IHC
PTT 
FISH        IHC 
Patient 1 IDC FA 1.1           2+ 1.3             2+ 
Patient 2 IDC FA 2.3           2+ 1.1             2+ 
Patient 3 LC TDH 1.2           2+ 1.2             2+ 
Patient 4 IDC FA 4.6           3+ 7.6             2+ 
Patient 5 IDC FC +FA+ TDH 7.5           3+ 5.1             2+ 
Patient 6 IDC FC + SA 3.7           3+ 1.8             2+ 
Patient 7 IDC FA  5.2           3+ 3.4             2+ 
Patient 8 IDC TDH + AM + PM 1.5           2+ 2.4             2+ 
Patient 9 IDC FC + AM + TDH 2.8           2+ 2.2             2+ 
Patient 10 IDC FC 2.1           2+ 1.4             2+ 
 
Table 10. Comparison between HER2 IHC overexpression and gene amplification in breast 
cancer and autologous multiple peritumoral tissues 
 
 
 
 
Figure 25. HER2 gene amplification in breast cancer (A) and PTT (B) sample by FISH analysis 
 
B A 
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3.3. Fas and FasL expression in benign mammary lesions, breast cancers and multiple 
PTT 
Figure 26 shows loss of Fas reactivity in breast cancer and Fas positivity in PTT 
samples. Table 11 reports that 40 out of 44 benign lesions (90.9%) showed a strong and 
homogeneous Fas expression prevalently localized on cell membrane whereas only 22% of 
benign tumors were FasL positive. On the other hand, when the 72 malignant tumors were 
evaluated, only 41 BC (56.9%) showed Fas positivity that was often heterogeneous in 
intensity and cell distribution whereas FasL (figure 27) was positive in 45.8% of the cases. 
The rate of cases expressing Fas was significantly lower in BC than in BL (p<0.0001) as well 
as the rate of FasL positive cases was significantly higher in BC than in BL (p<0.001). In both 
cases tumor-infiltrating lymphocytes provided internal controls. In BC the expression of 
receptor and ligand antigens appeared to be inversely related (p<0.0001) with 37.5% of 
Fas+/Fas-L− and 26.4% Fas−/Fas-L+. Double positive (Fas+/Fas-L+) and double negative 
(Fas−/Fas-L−) phenotypes accounted for 19.4% and 16.7% respectively. 
 
 
 
Figure 26. Loss of Fas reaction in breast cancer (A) and Fas positivity in PTT sample (B) 
 
 
 
Figure 27. FasL immunostaining in breast cancer (A) and PTT sample (B) 
A 
A B 
B
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Antigenic 
phenotype 
Benign lesions 
44 pts 
% Fas positivity 
(%) 
FasL positivity 
(%) 
Fas+ FasL+ 8 18.1   
Fas- FasL+ 2 4.5   
Fas+ FasL- 32 72.9 90.9 22.7 
Fas- FasL- 2 4.5   
  Breast cancer 
72 pts 
 Fas positivity 
(%) 
FasL positivity 
(%) 
Fas+ FasL+ 14 19.4   
Fas- FasL+ 19 26.4   
Fas+ FasL- 27 37.5 56.9 45.8 
Fas- FasL- 12 16.7   
  PTT 1 cm 
72 pts 
 Fas positivity 
(%) 
FasL positivity 
(%) 
Fas+ FasL+ 23 31.9   
Fas- FasL+ 7 9.7   
Fas+ FasL- 40 55.5 87.5.3 41.6 
Fas- FasL- 2 2.8   
  PTT 2 cm 
65 pts 
 Fas positivity 
(%) 
FasL positivity 
(%) 
Fas+ FasL+ 15 23.1   
Fas- FasL+ 3 4.6   
Fas+ FasL- 44 67.7 90.8 27.7 
Fas- FasL- 3 4.6   
  PTT 3 cm 
43 pts 
 Fas positivity 
(%) 
FasL positivity 
(%) 
Fas+ FasL+ 8 18.7   
Fas- FasL+ 2 4.6   
Fas+ FasL- 31 72.1 90.7 23.3 
Fas- FasL- 2 4.6   
 
Table 11. Evaluation of the contemporary expression of Fas and FasL in multiple tissue 
samples from 44 patients with benign mammary lesions and 72 patients with breast cancer 
 
The percentage of Fas expression in normal appearing breast epithelium in the three different 
samples adjacent to invasive cancer was similar to that observed in BL independently of the 
distance from the autologous BC (90.9% vs 87.5% at 1 cm, 90.8% at 2 cm, 90.7% at 3 cm). In 
contrast, FasL was significantly upregulated in PTT sampled at 1 cm with respect to BL 
(22.7% p=0.05). Therefore the percentage of FasL positive cases in 1cm PTT (41.6%) was 
similar to that found in BC (45,8%) and no statistically significant difference was evidenced 
between invasive cancer and the closest PTT (p=0.73). FasL expression in breast specimens 
collected farther from the autologous BC was similar to that observed in BL (22.7% vs. 
27.7% at 2 cm, 23.3% at 3 cm) and significantly different from BC (p= 0.04 at 2 cm and 
p=0.02 at 3 cm). 
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3.4. COX2 expression in breast cancer and metastatic lymph node specimens 
Clinicopathological characteristics of patients of the COX2, hormone receptors, 
HER2, p53, Ki67, Fas, FasL, PGE2S and EGFR investigations are shown in table 12. 
 
Characteristics Total number of patients = 186 
 No % 
Age = 48.12 (range 25-66) - - 
Tumor size 
<2 cm 
>2 cm 
 
183 
3 
 
98.4 
1.6 
Histotype 
Ductal carcinoma 
Lobular carcinoma 
 
154 
32 
 
82.8 
17.2 
Nodal Status 
No 
N1 
 
91 
95 
 
48.9 
51.1 
ER (cut off > 10%) 
Positive 
Negative 
 
94 
92 
 
50.5 
49,5 
PgR (cut off > 10%) 
Positive 
Negative 
 
103 
83 
 
55.4 
44.6 
HER2o 
Positive 
Negative 
 
74 
112 
 
39.8 
60.2 
P53 
Positive 
Negative 
 
76 
110 
 
40.9 
59.1 
COX2 
Positive 
Negative 
 
147 
39 
 
79.0 
21. 
PGE2S 
Positive 
Negative 
 
101 
20 
 
83.5 
16.5 
EGFR 
Positive 
Negative 
 
82 
85 
 
49.1 
50.9 
Fas 
Positive 
Negative 
 
107 
79 
 
57.5 
42.5 
FasL 
Positive 
Negative 
 
91 
95 
 
48.9 
51.1 
Relapse 
Positive 
Negative 
 
60 
126 
 
32.2 
67.8 
Cancer-related death 
Alive 
Dead 
 
148 
33 
 
81.7 
18.3 
 
Table 12. Clinicopathologic and biologic characteristics of 186 breast cancer patients 
 
Patients had a mean age of 48.12 years (range 25-66), including pre- and 
postmenopausal women. Of the 186 breast carcinomas 154 were infiltrating ductal carcinoma 
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and 32 infiltrating lobular carcinoma. Tumor sizes varied from T1 to T4 (T1 in 98 cases, T2 in 
85 cases, T3 in 2 case and T4 in 1 case). Ninety-one patients were node negative while 95 
tumors had already nodal metastases. Estrogen receptor positivity was found in 94 cases and 
103 tumors were progesterone receptor positive. Seventy-four malignant lesions 
overexpressed HER2 and 76 proved to be p53 positive. COX2 was expressed in 147 breast 
cancer specimens while 39 cases were COX2 negative. PGE2S positivity occurred in 101 
cases out of the 121, while 82 of the 167 samples investigated expressed EGFR. Fas positivity 
occurred in 107 cases and 91 lesions showed FasL reactivity. Sixty patients had relapse and 
33 patients died of the disease. 
COX2 immunoreactivity in primary tumors (figure 28A) and in metastatic lymph node 
samples (figure 28B) is described in table 13. Of the 82 COX2 positive primary tumor, 81 
(98.8%) had COX2 positive metastatic nodes while in 1 case (1.2%) nodal metastasis was 
COX2 negative. Among the 13 COX2 negative metastatic primary tumor, 9 (69.2%) had 
COX2 positive metastatic nodes, while in 4 cases (30.8%) we found no COX2 expression in 
the metastatic lymph nodes. Altogether, increase in expressing COX2 was found in metastatic 
lymph nodes regarding primary tumors (93.7% vs 86.5%). 
 
  
 
Figure 28. COX2 positivity in breast cancer (A) and in metastatic lymph node (B) 
 
N° of Patients Primary Tumor Lymph nodes 
81 + + 
1 + - 
9 - + 
4 - - 
Total (95) 82 (84.3%) 91 (95.7%) 
 
Table 13. COX2 reactivity in breast cancer samples and their metastatic lymph nodes 
A B 
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Table 14 shows the increased COX2 expression among metastatic lymph nodes versus 
primary tumors too. Of the 10 patients with 1 metastatic node each, 5 had COX2 positive 
primary tumor and 7 had COX2 positive metastases. Among the 15 patients, each with 2 
metastatic nodes, all primary tumors expressed COX2 and only 1 metastatic node was found 
to be COX2 negative. Three metastatic nodes per breast cancer were found in 21 patients, of 
which 19 primary tumors expressed COX 2 and 20 cases exhibited COX2 positive nodes. Ten 
patients had 4 metastatic nodes each, 9 of them being COX2 positive in primary tumor and 10 
cases being COX2 positive regarding the metastatic nodes. Seven of the 8 cases with 5 
metastatic lymph nodes each were found to express COX2 in the primary tumor and all the 
cases exhibited COX2 positive metastases. Among the 11 patients, each having 6 metastatic 
nodes, 10 were found to have COX2 primary tumors and all the cases had COX2 positive 
metastases. Of the 5 cases with 7 metastatic nodes each, 3 primary tumors were COX2 
positive while all cases were COX2 positive regarding the metastatic lymph nodes. Of the 6 
cases, each with 8 metastatic nodes, all cases were found to express COX2 both in primary 
tumors and metastatic lymph nodes. Five patients had breast cancer with 9 metastatic nodes 
each, 4 of them having COX2 positive primary tumor and 4 of them having COX2 positive 
metastases. Among the 4 cases with 10 metastatic nodes each, all primary tumors and 
metastases expressed COX2. 
 
 
N° of 
Patients 
Primary 
Tumor 
COX2+ 
N° of 
metastatic 
lymph nodes 
No of cases 
with COX2 + 
metastatic 
lymph nodes  
 10 5 1 7 
 15 15 2 14 
 21 19 3 20 
 10 9 4 10 
 8 7 5 8 
 11 10 6 11 
 5 3 7 5 
 6 6 8 6 
 5 4 9 4 
 4 4 10 4 
Total  95 82 (84.8%)  89 (93.7%) 
 
Table 14. COX2 immunoreactivity in primary tumors and their metastatic lymph node samples 
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3.5. PGE2S expression in breast cancer cases 
As described in table 15, only 121 primary breast cancer cases had tissue samples 
available for PGE2S analysis. Of the 102 COX2 positive samples 94 (92.2%) showed PGE2S 
immunoreactivity, 8 cases (7.8%) were PGE2S negative. Among the 19 cases negative for 
COX2 expression, 7 cases (36.8%) showed PGE2S positivity and 12 cases (63.2%) did not 
express PGE2S. No metastatic lymph node tissue samples were available for PGE2S 
immunohistochemical reaction. PGE2S immunostaining is shown in figure 29A. 
 
 PGE2S in primary tumor  
COX2 in primary tumor + - Total 
 
+ 
 
 
94 (92.2%) 
 
8 (7.8%) 
 
102 (100.0%) 
- 7 (36.8%) 12 (63.2%) 19 (100.0%) 
 
Table 15. COX2 and PGE2S reactivity in 121 breast cancer patients 
 
 
Figure 29. PGE2S positivity (A) and EGFR immunostaining in breast cancer (B) 
 
 
3.6. EGFR expression in breast cancer cases 
Table 16 shows the results of EGFR immunostaining (figure 29B). Among the 186 
primary breast cancer cases 167 cases had tissue samples available for EGFR expression 
analysis. During the immunohistochemical analyses, 66 (46.5%) of the 142 COX2 positive 
samples expressed EGFR, while 76 samples (53.5%) were EGFR negative. Of the 25 samples 
showing no COX2 reactivity, 16 (64.0%) were EGFR positive and 9 samples (36.0%) were 
EGFR negative. No metastatic lymph node samples were available for further analysis. 
 
A B 
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 EGFR expression  
COX2 expression + - Total 
 
+ 
 
 
66 (46.5%) 
 
76 (53.5%) 
 
142 (100.0%) 
- 16 (64.0%) 9 (36.0%) 25 (100.0%) 
 
Table 16. COX2 and EGFR reactivity in 167 breast cancer patients 
 
3.7. Statistical analysis 
As shown on figure 30A and 30B, distinguishing COX2 positivity in primary tumors 
as score 1,2 and 3 caused no significant difference in impact on DFS when compared to 
scoring COX2 staining only positive and negative (p=0.017 vs. p=0.002). Thus, we 
considered COX2 expression only positive or negative in the followings. 
 
0
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Figure 30. Impact of COX2 expression on DFS (scored 1/2/3 vs scored +/-) 
 
Relationships between COX2, PGE2S expression and biopathological variables are shown in 
table 17. COX2 expression was significantly related to nodal status (p=0.01), Ki67 expression 
(p=0.009) and relapse (p=0.03) while no significant relationship was found between COX2 
expression and tumor size (p=0.93), tumor histotype (p=0.73), ER status (p=0.64), PgR status 
(p=0.35), HER2 expression (p=0.63), p53 status (p=0.15) and cancer-related death (p=0.25). 
PGE2S activity was significantly related to COX2 expression (p<0.0001) and relapse 
(p=0.03), borderline significance was found between PGE2S positivity and nodal status 
(p=0.08), ER status (p=0.07) and Ki67 expression (p=0.089), while no relationship was found 
B A 
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between PGE2S expression and tumor size (p=0.30), tumor histotype (p=0.65), PgR status 
(p=0.60), HER2 expression (0.12), p53 status (p=0.37) and cancer-related death (p=0.18). 
 
 Frequency of immunoreactive cases 
Variable No. of cases 
(186) 
COX2 
(%) 
p 
value 
No. of cases 
(121) 
PGE2S 
(%) 
p 
value 
Tumor size 
< 2 cm 
> 2 cm 
 
99 
87 
 
78.8 
79.3 
 
0.93 
 
66 
55 
 
80.3 
87.3 
 
0.30 
Histotype 
Ductal 
Lobular 
 
154 
32 
 
78.6 
81.3 
 
0.73 
 
101 
20 
 
84.2 
80.0 
 
0.65 
Nodal status 
N0 
N+ 
 
90 
96 
 
71.1 
86.5 
 
0.01 
 
57 
64 
 
77.2 
89.0 
 
0.08 
ER status 
Negative 
Positive 
 
92 
94 
 
80.4 
77.7 
 
0.64 
 
65 
56 
 
89.2 
76.8 
 
0.07 
PgR status 
Negative 
Positive 
 
83 
103 
 
75.9 
81.6 
 
0.35 
 
61 
60 
 
85.2 
81.7 
 
0.60 
HER2/neu 
Negative 
Positive 
 
112 
74 
 
83.9 
86.5 
 
0.63 
 
72 
49 
 
79.2 
89.8 
 
0.12 
p53 status 
Negative 
Positive 
 
110 
76 
 
75.5 
84.2 
 
0.15 
 
74 
47 
 
81.1 
87.2 
 
0.37 
COX2 
Negative 
Positive 
 
 
_ 
 
_ 
 
_ 
 
27 
94 
 
48.1 
83.6 
 
<0.0001 
Ki67 
<30 
>30 
 
 
109 
77 
 
72.5 
88.3 
 
0.009 
 
70 
51 
 
78.6 
90.2 
 
0.089 
Relapse 
Negative 
Positive 
 
 
126 
60 
 
81.0 
93.3 
 
0.03 
 
 
77 
44 
 
77.9 
93.2 
 
0.03 
Cancer-related 
death 
Alive 
Dead 
 
 
145 
36 
 
 
84.1 
91.7 
 
 
0.25 
 
 
93 
25 
 
 
80.6 
92.0 
 
 
0.18 
 
Table 17. Relationship between COX-2, PGE2S expression and biopathological variables 
 
Tables 18 and 19 summarize the results of univariate and multivariate analyses of prognostic 
factors for DFS and OS respectively. 
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Tumor size (OR=2.10, CI=1.25-3.51, p=0.05), nodal status (OR=3.76, CI=2.11-6.69, 
p<0.001), COX2 expression (OR=4.39, CI=1.59-12.11, p=0.004), PGE2S positivity (OR=3.36 
(CI=1.04-10.85, p=0.004), Ki67 expression (OR=1.95, CI=1.18-3.24, p=0.009), Fas positivity 
(OR=0.18, CI=0.10-0.31) and FasL expression (OR=3.28, CI=1.90-5.66) were found to be 
significant predictors of DFS in univariate analysis, while a borderline significance was found 
between DFS and p53 positivity (OR=1.60, CI=0.96-2.65, p=0.069). ER status (HR=1.02, 
CI=0.62-1.69, p=0.93), PgR expression (HR=1.06, CI=0.64-1.76, p=0.83) and HER2 
positivity (OR=1.01, CI=0.59-1.71) had no significant impact on DFS. When considering 
concomitant expression of different variables, patients with tumors expressing both COX2 
and p53 (OR=5.20, CI=1.58-17.13, p=0.007) or COX2 and PGE2S (OR=7.96, CI=1.09-57.96, 
p=0.04) were found to have significantly reduced DFS (data not shown). 
Tumor size (OR=2.17, CI=1.18-3.98, p=0.013), nodal status (OR=4.61, CI=2.16-3.83, 
p<0.001), COX2 expression (OR=3.50, CI=1.07-11.46, p=0.039), Ki67 positivity (OR=5.56, 
CI=1.71-18.09), Fas expression (OR=0.09, CI=0.03-0.29) and FasL expression (OR=1.96, 
CI=1.19-3.32) were significant predictors of DFS even in multivariate analyses. 
 
Predictors of OS are shown in table 19. In univariate analysis, tumor size (OR=2.38, CI=1.20-
4.70, p=0.013), nodal status (OR=3.89. CI=1.77-8.55, p=0.001), p53 positivity (OR=2.17, 
CI=1.12-4.21, p=0.02), Ki67 positivity (OR=2.43, CI=1.25-4.75, p=0.009), HER2 expression 
(2.68, CI=1.48-4.86), Fas positivity (OR=0.07, 0.03-0.16) and FasL expression (OR=6.19, 
CI=3.05-12.53) were significant predictors of OS, while a borderline significance was found 
between COX2 expression and OS (HR=3.15, CI=0.87-10.27, p=0.05). Histotype (OR=1.65, 
CI=0.70-3.89), PGE2S positivity (OR=2.66, CI=0.63-11.29, p=0.19), EGFR expression 
(OR=1.49, 0.79-2.82), ER status (OR=1.39, CI=0.72-2.69, p=0.33) and PgR status (OR=1.51, 
CI=0.79-2.91, p=0.22) had no significant impact on OS. 
Similarly to DFS, concomitant expression of COX2 and p53 in the primary tumors 
significantly influenced OS (OR=4.71, CI1.10-20.16, p=0.037), while in contrary to DFS, 
patients with tumors expressing both COX2 and PGE2S had not significantly reduced OS 
(OR=3.80, CI=0.51-28.25, p=0.19) (data not shown). 
In multivariate analysis, nodal status (OR=3.66, CI=1.66-8.07, p=0.001), HER2 positivity 
(OR=4.86, CI=1.12-20.99) and Fas expression (OR=0.03, CI=0.005-0.17) were significant 
predictors of OS, while a borderline significance was found between OS and tumor size 
(OR=1.87, CI= 0.93-3.79, p=0.081), p53 positivity (OR=1.89, CI=0.96-3.74, p=0.068), Ki67 
positivity (OR=1.83, CI=0.91-3.68, p=0.089) and FasL expression (OR=4.29, CI=0.97-
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18.88). Histotype (OR=2.37, CI=0.34-16.96), COX2 expression (OR=0.14, CI=0.02-1.26), 
PGE2S positivity (OR=1.73, CI=0.18-16.7), EGFR expression (OR=0.88, CI=0.20-3.83), ER 
status (OR=0.29, CI=0.05-1.70) and PgR status (OR=2.7, CI=0.48-15.4) had no influence on 
OS. 
 
 
 Univariate analysis Multivariate analysis 
Variable OR (95% CI) p value OR (95% CI) p value 
Tumor size 
(< 2 cm vs. > 2 cm) 2.10 (1.25-3.51) 0.005 2.17 (1.18-3.98) 0.013 
Nodal status 
(N0 vs. N+) 
3.76 (2.11-6.69) <0.001 4.61 (2.16-3.83) <0.001 
Histotype 
(ductal vs. lobular) 0.89 (0.45-1.75) 0.78 0.89 (0.25-3.19) 0.88 
COX2  
(positive vs. negative) 4.39 (1.59-12.11) 0.004 3.50 (1.07-11.46) 0.039 
PGE2S expression 
(positive vs. negative) 3.36 (1.04-10.85) 0.004 2.96 (0.69-12.7) 0.22 
EGFR expression 
(positive vs. negative) 1.44 (0.80-2.59) 0.37 0.84 (0.31-2.32) 0.78 
p53 status 
(positive vs. negative) 1.60 (0.96-2.65) 0.069 2.63 (0.90-7.71) 0.14 
Ki67 status 
(positive vs. negative) 1.95 (1.18-3.24) 0.009 5.56 (1.71-18.09) 0.019 
ER status 
(positive vs. negative) 1.02 (0.62-1.69) 0.93 0.42 (0.09-1.87) 0.34 
PgR status 
(positive vs. negative) 1.06 (0.64-1.76) 0.83 3.35 (0.75-15.08) 0.19 
HER2/neu  
(positive vs. negative) 1.01 (0.59-1.71) 0.96 0.61 (0.20-1.93) 0.48 
Fas 
(positive vs. negative 0.18 (0.10-0.31) <0.001 0.09 (0.03-0.29) 0.001 
FasL 
(positive vs. negative) 3.28 (1.90-5.66) <0.001 1.96 (1.19-3.32) 0.01 
 
 
Table 18. Univariate and multivariate analyses of prognostic factors for DFS in 186 breast 
cancer patients 
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 Univariate analysis Multivariate analysis 
Variable OR (95% CI) p value OR (95% CI) p value 
Tumor size 
(<2 cm vs. >2 cm)  2.38 (1.20-4.70) 0.013 1.87 (0.93-3.79) 0.081 
Nodal status 
(N0 vs. N1) 
3.89 (1.77-8.55) 0.001 3.66 (1.66-8.07) 0.001 
Histotype 
(ductal vs. lobular 
carcinoma) 
1.65 (0.70-3.89) 0.34 2.37 (0.34-16.96) 0.47 
COX2 expression 
(positive vs. negative) 3.15 (0.87-10.27) 0.050 0.14 (0.02-1.26) 0.15 
PGE2S expression 
(positive vs. negative) 2.66 (0.63-11.29) 0.19 1.73 (0.18-16.7) 0.69 
EGFR expression 
(positive vs. negative) 1.49 (0.79-2.82) 0.30 0.88 (0.20-3.83) 0.88 
p53 status 
(positive vs. negative) 2.17 (1.12-4.21) 0.02 1.89 (0.96-3.74) 0.068 
Ki67 status 
(positive vs. negative) 2.43 (1.25-4.75) 0.009 1.83 (0.91-3.68) 0.089 
ER status 
(positive vs. negative) 1.39 (0.72-2.69) 0.33 0.29 (0.05-1.70) 0.25 
PgR status 
(positive vs. negative) 1.51 (0.79-2.91) 0.22 2.7 (0.48-15.4) 0.35 
HER2/neu  
(positive vs. negative) 2.68 (1.48-4.86) 0.007 4.86 (1.12-20.99) 0.08 
Fas 
(positive vs. negative 0.07 (0.03-0.16) <0.001 0.03 (0.005-0.17) 0.002 
FasL 
(positive vs. negative) 6.19 (3.05-12.53) <0.001 4.29 (0.97-18.88) 0.109 
 
Table 19. Univariate and multivariate analyses of prognostic factors for OS in 186 breast 
cancer patients 
 
 
Impact of COX2 expression on DFS (p=0.002) can also be seen on figure 30B showing the 
Kaplan-Meier curves for 186 breast cancer patients. Figure 31A and 31B demonstrate the 
impact of p53 positivity on DFS (p=0.067) and OS (p=0.02) according to the Kaplan-Meier 
curves, while impact of concomitant expression of COX2 and p53 expression on DFS 
(p=0.003) and on OS (p=0.02) can be seen on figure 31C and 31D demonstrating the 
respective Kaplan-Meier curves. 
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Figure 31. Impact of p53 expression on DFS (A) and OS (C), and concomitant COX2/ p53 
expression on DFS (B) and OS (D) 
 
 
Results of determining relationships between prognostic factors are shown in table 20. COX2 
expression in primary breast tumors was significantly related to p53 expression (OR=2.917, 
CI=1.308-6.505) and Ki67 expression (OR=1.993, CI=1.001-3.970). There was a significant 
relationship between HER2 and FasL (OR=1.687, CI=1.026-2.774), Ki67 (OR=1.765, 
CI=1.068-2.916) and EGFR (OR=2.314, CI=1.320-4.056) positivity. ER expression was 
significantly related to Ki67 (OR=0.433, CI=0.264-0.710), p53 (OR=0.427, CI=0.258-0.706), 
PgR (OR=99.171, CI=40.558-242.489) and EGFR (OR=0.448, CI=0.255-0.786) expression, 
while PgR expression showed significant relationship to Ki67 (OR=0.360, CI=0.217-0.596), 
EGFR (OR=0.377, CI=0.214-0.664) and p53 (OR=0.481, CI=0.292-0.792) expression. p53 
expression was significantly related to FasL (OR=1.843, CI=1.122-3.028) and to Ki67 
(OR=2.540, CI=1.524-4.232) expression, while there was a significant relationship also 
between Fas and FasL expression (OR=0.245, CI=0.146-0.411). 
A B
C D
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Variable I Variable II OR 5% CI 95% CI 
FAS FASL 0.245 0.146 0.411 
Ki67 FASL 0.923 0.569 1.498 
EGFR FASL 0.935 0.575 1.730 
PGE2S FASL 1.306 0.595 2.866 
COX2 FASL 1.333 0.675 2.633 
p53 FASL 1.843 1.122 3.028 
HER2 FASL 1.687 1.026 2.774 
PgR FASL 0.966 0.595 1.570 
ER FASL 1.001 0.618 1.622 
Ki67 FAS 1.245 0.763 2.031 
EGFR FAS 1.094 0.628 1.904 
PGE2S FAS 0.831 0.378 1.825 
COX2 FAS 1.019 0.515 2.014 
p53 FAS 0.781 0.476 1.282 
HER2 FAS 1.040 0.632 1.713 
PgR FAS 0.818 0.500 1.338 
ER FAS 0.833 0.511 1.358 
EGFR Ki67 1.226 0.703 2.136 
PGE2S Ki67 0.885 0.407 1.928 
COX2 Ki67 1.993 1.001 3.970 
p53 Ki67 2.540 1.524 4.232 
HER2 Ki67 1.765 1.068 2.916 
PgR Ki67 0.360 0.217 0.596 
ER Ki67 0.433 0.264 0.710 
PGE2S EGFR 0.770 0.304 1.948 
COX2 EGFR 1.873 0.845 4.155 
p53 EGFR 1.435 0.818 2.515 
HER2 EGFR 2.314 1.320 4.056 
PgR EGFR 0.377 0.214 0.664 
ER EGFR 0.448 0.255 0.786 
COX2 PGE2S >1.7 x 107 >1.7 x 107 >1.7 x 107 
p53 PGE2S 1.714 0.753 3.905 
HER2 PGE2S 0.000 0.000 0.000 
PgR PGE2S 1.275 0.586 2.776 
ER PGE2S 0.000 0.000 0.000 
HER2 COX2 1.226 0.608 2.471 
PgR COX2 0.919 0.465 1.816 
ER COX2 0.515 0.256 1.036 
p53 COX2 2.917 1.308 6.505 
HER2 p53 1.417 0.859 2.336 
PgR p53 0.481 0.292 0.792 
ER p53 0.427 0.258 0.706 
PgR HER2 0.697 0.424 1.145 
ER HER2 0.882 0.539 1.444 
ER PgR 99.171 40.558 242.489 
 
Table 20. Relationship of the investigated biopathological variables detemined by OR 
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4. DISCUSSION 
The observation that small invasive BC, in some cases, are not preceded by atypical 
hyperplasia or in situ carcinoma, usually present in the earliest stages of breast 
carcinogenesis, suggests that many molecular alterations in tumor development may be 
morphologically silent (6, 113, 114). Therefore, the identification of biological changes 
occurring in normal appearing tissue surrounding invasive cancer are pivotal for 
understanding BC pathogenesis and for risk assessment of pre-invasive lesions. In view of 
observation that high levels of carcinogen DNA adducts (115), loss of retinoic acid receptor β 
(116) and changes in chromosome copy number (2) may occur in normal PTT, we performed 
the present study aimed at assessing whether breast epithelium adjacent to invasive cancer 
may express markers of transformation. For an easy clinical application, we chose IHC as 
method of analysis. Several studies have identified a number of molecular changes involving 
oncogenes (9) and tumor suppressor genes (117), which can increase the risk of developing 
invasive carcinoma in some types of pre-invasive breast lesions. In contrast, limited studies 
compared molecular alterations between cancer and the autologous adjacent breast tissue (10, 
117, 118) and, to the best of our knowledge, no studies evaluated contemporary multiple non-
involved tissues sampled from the same patient. In fact, it could be hypothesized that the 
closer a lesion is to invasive end-stage, the more it will resemble to the invasive cancer from a 
molecular point of view. Starting from this consideration, in this study we analyzed PTT 
sampled at 1, 2, 3 cm from the autologous tumor to ascertain whether a gradient of detectable 
molecular changes may exist. It is largely reported that besides proliferation, reduced 
apoptosis can lead to preservation of genetically aberrant cells, thus favoring initiation of 
breast oncogenesis (119). To this end we investigated the expression of markers relevant in 
both the two processes, namely HER2, a member of the EGFR family known to be 
overexpressed in early stages of BC (120, 121), p53, frequently mutated in invasive mammary 
carcinoma (117) and the interacting extracellular pro-apoptotic receptor/ligand pair, Fas/Fas-
L, inversely expressed in malignant breast tumors with respect to the benign lesions (122-
124). In our series of 72 BC patients HER2 was overexpressed (score 2+/3+) in 26.3% of 
cases. In addition, as described by other authors (6, 9, 117, 118), we found variable levels of 
HER2 positivity (score 1+/2+) in a low percentage of benign lesions and in some normal 
appearing PTT independently of the distance from the autologous BC. This immunoreactivity 
was prevalently detected in FA, TDH and ADH. Although alteration of HER2 status was 
described in a large spectrum of benign lesions (6, 9) and in non-neoplastic epithelium present 
on the same tissue sections as cancer (10, 117, 118), the biological significance of this HER2 
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immunoreactivity in non-transformed breast tissue is still a matter of debate, being mostly 
considered as false positive staining (125). This is in contrast with the finding that HER2 
amplification can emerge de novo in any stage of breast carcinogenesis, may be detectable in 
typical as well as atypical ductal hyperplasia (10, 118, 120) and, noteworthy, women carrying 
benign proliferative lesions harboring amplified HER2 are at higher risk of developing cancer 
(9, 10). In order to better understand the biological basis of HER2 immunoreactivity in 
morphologically uninvolved PTT, we evaluated, by FISH analysis, gene amplification in the 
10 PTT sampled at 1, 2 or 3 cm with HER2 immunostaining. Of interest, gene amplification 
was detected in 5 of these cases, independently from the distance from the autologous BC and 
in 8 out of 10 corresponding invasive cancer, demonstrating that the IHC HER2 positivity in 
normal-appearing breast epithelium has often underlying HER2 gene amplification. 
We detected p53 nuclear staining in a limited number of benign lesions as well as in multiple 
PTT. The positivity, as already observed for HER2, was not related to the distance from the 
primary tumor and no statistical significance among specimens collected at 1, 2 and 3 cm 
(p=0.21, p=0.42 and p=0.99 respectively) was found. These results are of clinical interest 
since it has been recently reported that p53 immunostaining in benign epithelial cells, even if 
weak and focal, appears to be associated with a statistically significant increased risk of BC 
development (6, 126). That even a weak immunostaining is predictive of transformation, may 
be questionable, because p53 inactivated by mutation is usually associated to strong and 
diffuse nuclear accumulation (127). However, low levels of p53 protein could be a marker of 
cells more easily exposed to a carcinogenic microenvironment, leading to increased genetic 
instability and consequent tumor initiation. 
Fas and FasL interactions, which play an important role in different immune functions (122-
124), are crucial in the involution of the mammary epithelium preventing cellular 
accumulation of mutations and neoplastic transformation (128). It is largely reported (11, 13, 
119, 129) that benign and malignant breast lesions are characterized by different expression of 
Fas and FasL molecules. In agreement with other authors (13, 129), we demonstrated that 
altered FasL:Fas ratio in breast carcinomas is related to adverse clinical outcome. Moreover, 
this is the first report in which Fas and FasL expression was accurately analyzed in malignant 
breast tumors and autologous normal appearing breast epithelium collected at different 
distance from invasive cancer. Fas expression was significantly downregulated in our series 
of primary tumors (130-132), but it was homogeneously expressed in PTT independently of 
the distance from the autologous BC (87.5%, 90.8% and 90.7% respectively). Therefore 
changes in Fas expression, which in the tumor may be inactivated by different molecular 
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mechanisms such as promoter methylation, transcriptional repression and histone acetylation 
(133), do not seem to be an early event in breast carcinogenesis. Although we do not know 
the mechanism/s underlying Fas downregulation in BC, this change may result in resistance to 
apoptosis i.e. accumulation of genetic changes and decrease of NK cell mediated 
immunosurveillance (131). Differently from Fas, FasL was significantly upregulated in 
malignant tumor samples (45.5%) and PTT closer (1 cm 41.7%) to the tumor with respect to 
BL (22.7%) and to PTT sampled at 2 cm (27.7%) and at 3 cm (23.3%) from the autologous 
BC. FasL in non-lymphoid tissues is known to be induced by a number of factors among 
which the response to activated lymphocytes has been extensively documented (134, 135). 
Whether this latter mechanism is responsible for FasL upregulation in about 50% of breast 
cancer, in 20% of benign lesions and interestingly in 41.7% of the PTT nearest to the tumor is 
unclear at present. One may hypothesize that in some patients FasL expression may be 
induced by circulating T cells recognizing MHC-peptide complexes on tumor cells. Although 
we cannot exclude that FasL upregulation in surrounding PTT may be induced by a paracrine 
mechanism (2, 136), the same immune-mediated upregulation may also occur in apparently 
normal breast tissues. Whatever the molecular pathways responsible for FasL expression are, 
this new phenotype is likely to result in being protected against T cell mediated killing, thus 
facilitating the accumulation of cell damages in benign lesions leading to malignant 
transformation. 
In conclusion, our results indicate that HER2 positive breast cancers may have underlying 
gene amplification not only in the BC itself but also in the morphologically normal-appearing 
adjacent parenchyma. We have also shown that p53 nuclear accumulation can be observed in 
a small percentage of PTT. Neither HER2 nor p53 showed a gradient of alterations starting 
from the closest to the farther PTT, suggesting that these two molecules in benign tissue of 
cancer-containing breast could reflect a genomic damage due to long-term carcinogenic 
exposure. In contrast, a gradient of expression was evident for FasL since the PTT closest to 
invasive cancer showed an upregulated FasL and this upregulation was lost in PTT farther 
from the invasive carcinoma. These data support the hypothesis that FasL, in combination 
with other biological parameters, may be a novel biomarker useful to identify patients at 
higher risk of developing BC. 
In women, bearing genetic or environmental risk factors, random periareolar fine-needle 
aspirates (FNA) may be a simple available tool to identify individuals at very high short-term 
risk for BC (126). In this context the completion of conventional morphological 
characterization with a molecular assessment using multiple biomarkers as surrogate end 
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points, makes cytological diagnosis less susceptible to interpretative variance. Therefore the 
availability of novel molecules, i.e. Fas-FasL, easy to detect by IHC in FNA, used in 
combination with more established parameters such as HER2 and p53, may be of particular 
diagnostic interest being predictive of later cancer development. To this end, larger 
prospective studies, aimed at establishing the clinical relevance of the present findings, are 
warranted. 
Our results obtained by analyzing immunohistochemically 186 stage I-II primary breast 
tumors and 95 autologous lymph node metastases for COX2, PGE2S, EGFR, hormones 
receptor, HER2, p53, Ki67, Fas and FasL expression demonstrate that tumor size, nodal 
status, COX2, PGE2S, Ki67, Fas and FasL expression were significant predictors of DFS 
while OS was significantly influenced by tumor size, nodal status, COX2, p53, Ki67, HER2, 
Fas and FasL expression. Besides a marked increase (11.4%) in COX2 expression in 
metastases versus primary tumors, significant correlation between COX2 expression and 
nodal status was found in our investigations. This finding may be explained with the data 
obtained by a study on murine model of metastatic breast cancer, where in contrast to the 
uniform in vitro COX2 expression, only tumors resulting from the transplantation of 
metastatic cell lines expressed COX2 in vivo suggesting that 
i) in the tumor milieu, COX2 expression may be regulated differently in non-
metastatic versus metastatic lesions (30) and that 
ii) constitutive expression of COX2 may be required to maintain the altered phenotype 
of increased invasiveness (137). 
Our samples showed a significant correlation between COX2 and PGE2S expression in breast 
tumors. This finding is not unexpected, since human breast cancers were shown by others to 
contain high levels of PGE2 provided by the breast fibroblasts under the influence of 
inflammatory mediators (138), and the ability of breast tumors to produce PGE2 is also related 
to high COX2 expression and metastatic potential (138). PGE2S was also related to ER 
expression in our samples. These results can be explained by the findings that the aromatase 
enzyme complex, which catalyzes estrogen biosynthesis, is regulated by PGE2 via four 
transmembrane receptors (139) and via induction of interleukin-6 (140), thus providing the 
increased estrogen level fundamental to hormone-dependent growth of breast cancer. 
In our series of samples we also found that COX2 was significantly related to Ki67 
expression. Ki67 is a widely accepted marker of proliferation (141, 142), thus, in accordance 
with other authors (143, 144), relationship between Ki67 and other markers of unfavorable 
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outcome, such as COX2, may be based on the worse prognosis related to poorly differentiated 
and intensively proliferating cancers. 
p53 expression alone significantly influenced only OS but not DFS, while when considering 
concomitant COX2 and p53 expression, this combination had a significant impact both on 
DFS and OS among our samples. Traditionally, p53 overexpression by 
immunohistochemistry is thought to represent TP53 mutation, however, high concordance of 
increased p53 protein is only seen with missense mutations, which result in protein that is 
resistant to degradation and has longer half-life than the wild-type (wt) counterpart (145). 
Furthermore, our present data imply that breast tumors overexpressing p53 and COX2 have a 
significantly poorer DFS (p=0.003) and OS (p=0.02) than those with normal low pattern of 
p53 expression and no expressed COX2. Because the COX2 gene has been shown to be 
induced in p53 defective cells and down-regulated by wt p53 (146), there may exist a direct 
link between a defective p53 pathway and elevated levels of COX2 expression in cancer cells. 
Though we did not investigate that the expressed p53 protein in our samples were wt or 
mutant, our results indicate that the p53 protein expressed in the breast tumor samples may be 
at least partly defected mutant p53 protein thus failing to repress COX2 expression. 
In contrast to the model system, COX2 expression was not associated to either EGFR or 
HER2 expression. Possible explanations, as offered by other authors (24, 147-151), are as 
follows: 
(i) Tumor tissue specimens represent a different environment from those in in vitro 
models. The production of growth factors as EGFR as well as COX2 synthesis by endothelial 
and stromal cells contribute to realization of a regulatory microenvironment which might not 
fit the straight biochemical relationships found in cell culture models (147). 
(ii) The association between high EGFR expression and poor response to 
chemotherapy was reported in studies utilizing a radioligand assay for EGFR determination 
(148, 149), while no association between EGFR and response to chemotherapy or clinical 
outcome was reported in cases of immunohistochemical assessment of EGFR expression 
(150, 151). This suggests that the methodological approach could heavily affect the evaluation 
of the prognostic value of the marker. 
(iii) COX2 expression is regulated by other signaling pathways in addition to those 
promoted by the erb-B family members. In this context it is worth noting that inhibition of 
HER2/HER3 complex formation in colon cancer cells failed to completely inhibit COX2 
protein expression (24). 
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We also demonstrated that in accordance with a cell culture model system (28) and another 
clinical study (152), EGFR and HER2 are associated one another. Furthermore, EGFR 
correlated with ER and PgR expression, which is in accordance with other findings (152). 
These results are not unexpected since it is postulated that estrogen or estrogen-regulated 
proteins are involved in the regulation of EGFR mRNA and protein (28), and that expression 
of ER and EGFR is required for controlling tumor proliferative activity in vitro (153). 
ER was related to p53 expression. Since ER has been shown physically associate with the 
amino terminus of p53 to form complexes and protect p53 from degradation, it is highly 
probable that ER signaling results in the up-regulation of p53 expression to mediate G1 cell 
cycle arrest (reviewed in 154). As mentioned above, in presence of non-functional (mutant) 
p53, despite of p53 overexpression, cell cycle has already broken loose from under control. 
Relationship between ER and Ki67 expression may be explained by the finding that activated 
ER can activate the mitogen activated protein kinase pathway (MAPK) thus resulting in 
increased proliferation (154). 
Since ER is a key transcription factor for the activation of PgR and thus expression of PgR is 
highly regulated by ER expression (155), explanation of PgR expression related to Ki67, 
EGFR and p53 expression may be the same as provided for ER expression. 
In accordance with other findings (143, 156), HER2 expression was significantly related to 
Ki67 expression and thus to high proliferation rate, which may be explained by an indirect 
relationship originating from both factors being well-known related to poor histological 
differentiation and increased malignancy of the disease. 
p53 and FasL expression were significantly correlated, though no connection was observed 
between p53 and Fas. This finding further supports the hypothesis that p53 expressed in our 
tumor samples was non-functional, being able to induce FasL (157) but not Fas transcription 
(158), and unable to repress COX2 expression. 
A significant relationship was found between HER2 and FasL expression. According to a 
spontaneous tumor model, concomitant HER2 and FasL expression is necessary for 
developing tumors being able to escape active specific immunotherapy by inducing apoptosis 
in tumor infiltrating T lymphocytes (159). These findings suggest that in patients with breast 
cancers overexpressing both biologic markers, the possibility of developing escape tumors 
must be considered when determining the most suitable therapy. 
Fas and FasL expression was found to be significantly related to each other in our series of 
samples, with a consequence of more favorable prognosis than in patients with no Fas and 
FasL expression. This finding is not unexpected, since the Fas-FasL apoptotic system is 
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required for eliminating tumor cells, thus malignant cells with an intact apoptotic system are 
more probable to be eliminated than cells with a defective or completely missing Fas-FasL 
system (130, 133, 135). 
Biologic markers used to determine prognosis of breast cancer patients are expressed as a net 
result of deregulated cell proliferation, thus concomitant evaluation of expression of these 
factors provide more accurate information on disease progression than independent 
investigation of the individual prognostic factors. Our results suggest that elevated expression 
of COX2 associates with poorer DFS and OS in breast cancers. Elevated PGE2S activity in 
COX2 positive tumors derives from alteration in COX2 expression and results in ensured 
growth of hormone dependent tumor and in higher metastatic potential. Expression of COX2 
associated with altered expression of tumor suppressor gene p53 and proliferative marker 
Ki67 may in part be responsible for induction of COX2 expression in breast cancer. 
In conclusion, our data indicate that in high-risk breast cancer patients the 
immunohistochemical evaluation of COX2, together with PGE2S, p53, Ki67, HER2, Fas and 
FasL, may be of clinical value in distinguishing different responses to adjuvant anthracycline-
based chemotherapy. Furthermore, HER2 copy number determined by FISH not only in the 
tumor itself but also in the normal-appearing PTT may be of help in determining more 
accurate prognosis. 
 
5. NEW STATEMENTS 
 
1. In 5 cases out of the 10 HER2 positive peritumoral tissue samples (1cm) investigated 
showed HER2 amplification, thus supporting the hypothesis that the morphologically 
normal-appearing breast tissue already harbours molecular changes which may predict 
malignant transformation. 
2. A gradient of expression was evident for FasL since the peritumoral tissues closest to 
invasive cancer showed an upregulated FasL (p=0.05) and this upregulation was lost 
in PTT farther from the invasive carcinoma (p=0.04 at 2 cm, p=0.02 at 3 cm). Thus, 
FasL, in combination with other biological parameters, may be a novel biomarker 
useful to identify patients at higher risk of developing recurrent breast cancer. 
3. Tumor size, nodal status, COX2, PGE2S, Ki67, Fas and FasL expression were 
significant predictors of DFS (p=0.005, p<0.001, p=0.004, p=0.004, p=0.009, p<0.001 
and p<0.001 respectively) while OS was significantly influenced by tumor size, nodal 
status, COX2, p53, Ki67, HER2, Fas and FasL expression (p=0.013, p=0.001, p=0.05, 
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p=0.02, p=0.009, p=0.007, p<0.001 and p<0.001 respectively). Out of these 
investigated markers, COX2 and PGE2S may be used as new prognostic markers for 
breast cancer. 
4. Concomitant overexpression of COX2 and p53 has significantly decreased 5 year 
disease free survival (p=0.003) and overall survival (p=0.02). 
5. In high-risk breast cancer patients the immunohistochemical evaluation of COX2, 
together with PGE2S, p53, Ki67, HER2, Fas and FasL, may be of clinical value in 
distinguishing different responses to adjuvant anthracycline-based chemotherapy. 
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